Potency enhancing sequences for subcutaneously administrated, subcutaneously localizing, or adipocyte targeting gene therapies

Cis-delivered enhancer sequences in nucleic acid constructs improve subcutaneous gene therapy potency and safety by promoting localized expression and systemic distribution of therapeutic proteins, addressing the underutilization and inefficiencies of subcutaneous delivery.

WO2026241468A1PCT designated stage Publication Date: 2026-11-19REMEDIUM BIO INC +6
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028102
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Subcutaneous gene therapy delivery has been underutilized and the factors influencing potency following subcutaneous delivery, particularly in non-viral systems, are not well understood, leading to reduced therapeutic efficacy and safety concerns due to systemic vector exposure.

Method used

Incorporation of cis-delivered enhancer sequences, such as specific enhancer-spacer-Kozak architectures, within nucleic acid constructs to enhance gene expression and localization in subcutaneous tissues, allowing for localized transgene expression and systemic distribution of therapeutic proteins.

Benefits of technology

Improves the potency and safety of subcutaneously administered gene therapies by maintaining genetic material near the injection site, reducing systemic vector exposure, and enhancing therapeutic protein secretion and distribution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028102_19112026_PF_FP_ABST
    Figure US2026028102_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides, at least in part, cis-delivered upstream potency enhancing sequences for subcutaneously administered gene therapies and their application to subcutaneous delivery of genetic medicine using viral and non-viral vectors. Related compositions and methods are provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] R0872.70016WQ00

[0002] POTENCY ENHANCING SEQUENCES FOR SUBCUTANEOUSLY ADMINISTRATED, SUBCUTANEOUSLY LOCALIZING, OR ADIPOCYTE TARGETING GENE THERAPIES

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 63 / 805,214, filed May 13, 2025, entitled “POTENCY ENHANCING SEQUENCES FOR SUBCUTANEOUSLY ADMINISTRATED, SUBCUTANEOUSLY LOCALIZING, OR ADIPOCYTE TARGETING GENE THERAPIES”, the entire disclosure of which is hereby incorporated by reference in its entirety.

[0004] REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0005] The contents of the electronic sequence listing (R087270016WO00-SEQ-JAV.xml; Size: 174,488 bytes; and Date of Creation: May 12, 2026) are herein incorporated by reference in their entirety.

[0006] FIELD OF THE INVENTION

[0007] The present invention provides, at least in part, cis-delivered upstream potency enhancing sequences for subcutaneously administered gene therapies and their application to subcutaneous delivery of genetic medicine using viral and non-viral vectors. Related compositions and methods are provided.

[0008] BACKGROUND OF THE INVENTION

[0009] Genetic medicine has emerged as a powerful therapeutic modality for the treatment of a wide array of human and veterinary pathologies. By delivering nucleic acid constructs that encode therapeutic proteins or peptides, gene therapy enables precise modulation of biological processes at the molecular level. Gene therapy treatments offer significant therapeutic potential for a broad range of pathologies. Systemic administration of gene therapy vectors, particularly viral vectors, has been the predominant route for achieving therapeutic protein expression. However, systemic delivery is often associated with preferential localization of the vector to the liver, spleen, and other highly perfused organs. This biodistribution pattern is accompanied by several significant limitations, includingvector-associated toxicity, immunogenicity, and antigenicity, which collectively reduce the therapeutic index and limit applicability of gene therapy to broader patient populations.

[0010] SUMMARY OF THE INVENTION

[0011] Subcutaneously administered gene therapies offer a means to deliver genetic material to predominantly non-life- / non-function-sustaining tissues, and when coupled with adipocyte targeting or subcutaneous localization factors, the DNA can remain relatively local to the subcutaneous area of injection, while the produced and secreted therapeutic protein can biodistributed systemically to mediate its intended effect. Subcutaneous administration of gene therapies presents an underutilized route of delivery that offers several advantages. When DNA vectors are delivered subcutaneously, particularly in combination with adipocytetargeting moieties or subcutaneous-localizing sequences, the genetic material can remain localized near the site of administration when the vector and / or genetic cassette provide for such localization. This localization facilitates persistent transgene expression in non-life- / non-function-sustaining tissues and can enable the encoded therapeutic protein or peptide to be secreted and distributed systemically to achieve distal pharmacologic effects. Such an approach reduces systemic vector exposure and may offer an improved safety profile, particularly for repeated or chronic administration scenarios.

[0012] Despite its promise, however, the subcutaneous route has previsouly been relatively unexplored in the field of genetic medicine. Factors that influence the potency of gene expression following subcutaneous delivery have been largely unknown, especially in the context of non- viral delivery platforms where transfection efficiency and expression are highly sensitive to construct and vector design. For example, factors that are related to upstream genetic enhancers delivered in cis are important for non-virally delivered DNA, however, factors that function within the liver may not be the same as those effective in the subcutis. Furthermore, the addition of genetic enhancers can increase construct size, and this can directly reduce the potency of non-virally delivered gene therapies. In particular, the size of the genetic cassette inversely correlates with potency in non- viral systems, underscoring the need for compact, efficient regulatory elements. Although the use of in cis enhancer elements has been studied for intramuscular or intravenous administration, their applicability and performance in subcutaneous gene therapy contexts have not been adequately

[0013] characterized.The present invention addresses this unmet need, at least in part, by providing cisdelivered enhancer sequences and their positions that can significantly improve the potency of subcutaneously administered gene therapies.

[0014] In one aspect, a nucleic acid construct, such as a circular nucleic acid construct, is provided comprising:

[0015] • a coding sequence encoding a protein or peptide;

[0016] • a polyadenylation signal positioned downstream of the coding sequence;

[0017] • a Kozak sequence operably linked to the coding sequence;

[0018] • a spacer sequence positioned upstream of the Kozak sequence; and

[0019] • at least one enhancer sequence positioned upstream of the Kozak sequence and separated from the Kozak sequence by the spacer sequence.

[0020] In one embodiment of any one of the compositions or methods provided herein, the enhancer sequence is positioned within 0 to 52 nucleotides upstream of the Kozak sequence.

[0021] In one embodiment of any one of the compositions or methods provided herein, the spacer sequence is between 0 and 52 nucleotides in length.

[0022] In one embodiment of any one of the compositions or methods provided herein, a start position of the spacer sequence is located between 2,031 and 7,271 nucleotides downstream of the polyadenylation signal.

[0023] In one embodiment of any one of the compositions or methods provided herein, positioning of the enhancer- spacer- Kozak architecture within said range results in increased expression of the encoded protein relative to positioning outside said range.

[0024] In one embodiment of any one of the compositions or methods provided herein, the enhancer sequence comprises a sequence having at least 85% identity to a sequence selected from: C[A / G]GGTT[G / T]G, GCGAAGCGCGCGGCGGGCGGGAG, CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, and GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCAGGGCT CAGGATA, optionally, positioned within 0 to 52 nucleotides upstream of the Kozak sequence.

[0025] In one embodiment of any one of the compositions or methods provided herein, the enhancer sequence is positioned between 18 and 23 nucleotides upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, thespacer sequence is between 0 and 18 nucleotides in length. In one embodiment of any one of the compositions or methods provided herein, the enhancer sequence is positioned between 18 and 23 nucleotides upstream of the Kozak sequence; and the spacer sequence is between 0 and 18 nucleotides in length.

[0026] In one embodiment of any one of the compositions or methods provided herein, the the enhancer sequence comprises a GC-rich sequence, a CpG-rich sequence, or a motif of the form C[A / G]GGTT[G / T]G.

[0027] In one embodiment of any one of the compositions or methods provided herein, the enhancer sequence is positioned between 18 and 23 nucleotides upstream of the Kozak sequence.

[0028] In one embodiment of any one of the compositions or methods provided herein, the spacer sequence comprises GTTGGACGCGTCGCTAGC or a sequence having at least 85% identity thereto.

[0029] In one embodiment of any one of the compositions or methods provided herein, the spacer sequence lacks translation initiation codons.

[0030] In one embodiment of any one of the compositions or methods provided herein, comprising a plurality of enhancer sequences. In one embodiment of any one of the compositions or methods provided herein, the plurality of enhancer sequences comprises a proximal enhancer positioned within 0-52 nucleotides upstream of the Kozak sequence; and / or a distal enhancer positioned upstream of the proximal enhancer.

[0031] In one aspect, a nucleic acid construct, such as a circular nucleic acid construct, is provided comprising a coding sequence; a polyadenylation signal downstream of the coding sequence; and any one of the enhancer-spacer-Kozak architectures provided herein.

[0032] In one embodiment of any one of the compositions or methods provided herein, the start position of the spacer sequence is located between 2,000 and 7,500 nucleotides downstream of the polyadenylation signal. In one embodiment of any one of the compositions or methods provided herein, the start position is between 2,031 and 7,271 nucleotides downstream of the polyadenylation signal.

[0033] In one embodiment of any one of the compositions or methods provided herein, wherein positioning of the enhancer-spacer-Kozak architecture outside the defined range results in reduced or non-detectable expression.

[0034] In one embodiment of any one of the compositions or methods provided herein, wherein expression is increased by at least 2-fold relative to a construct lacking the enhancer sequence.In one embodiment of any one of the compositions or methods provided herein, wherein inclusion of the enhancer sequence increases expression beyond levels predicted based on construct size.

[0035] In one embodiment of any one of the compositions or methods provided herein, the encoded protein is selected from GLP-1 or a variant thereof, FGF21, an antibody or antibody fragment, a cytokine or growth factor, optionally, fused to an Fc-receptor binding domain, albumin binding domain, or other fusion partner.

[0036] In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer C[A / G]GGTT[G / T]G, positioned with a 0-18nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer C[A / G]GGTT[G / T]G, positioned with a 0-23nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer C[A / G]GGTT[G / T]G, positioned with a 0-52nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a class of Series A sequences, positioned with a 0-18nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a class of Series A sequences, positioned with a 0-23nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCAGGGCT CAGGATA, positioned with a 0-18nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCAGGGCT CAGGATA, positioned with a 0-23nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCAGGGCT CAGGATA, positioned with a 0-52nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a class of Series A sequences, positioned with a 0-52nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions ormethods provided herein, the enhancer is an upstream enhancer ACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG, positioned with a 0-18nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer ACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG, positioned with a 0-23nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer ACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG, positioned with a 0-52nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CAGGTTGG, positioned with a 0-18nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CAGGTTGG, positioned with a 0-23nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CAGGTTGG, positioned with a 0-52nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a class of Series G sequences, positioned with a 0-18nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a class of Series G sequences, positioned with a 0-23nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a class of Series G sequences, positioned with a 0-52nt spacer upstream of the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG, positioned 316 to 264nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG, positioned 316 to 264nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG, positioned 316 to 264nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancerGCGAAGCGCGCGGCGGGCGGGAG, positioned 251 to 199nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG, positioned 251 to 199nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG, positioned 251 to 199nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series B sequences, positioned 316 to 264nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series B sequences, positioned 316 to 264nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series B sequences, positioned 316 to 264nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series B sequences, positioned 251 to 199nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series B sequences, positioned 251 to 199nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series B sequences, positioned 251 to 199nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 615 to 563nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 615to 563nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 615 to 563nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 581 to 529nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 581 to 529nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 581 to 529nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 932 to 840nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 932 to 840nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 932 to 840nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 295 to 203nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions ormethods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 295 to 203nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 295 to 203nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 581 to 529nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series C sequences, positioned 615 to 563nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series C sequences, positioned 615 to 563nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series C sequences, positioned 615 to 563nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series C sequences, positioned 581 to 529nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series C sequences, positioned 581 to 529nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series C sequences, positioned 581 to 529nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series C sequences, positioned 932 to 840nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of anyone of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series C sequences, positioned 932 to 840nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series C sequences, positioned 932 to 840nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series C sequences, positioned 295 to 203nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series C sequences, positioned 295 to 203nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series C sequences, positioned 295 to 203nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 850 to 798nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 850 to 798nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 850 to 798nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 798 to 746nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer

[0037] CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCA, positioned 798 to 746nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 798 to 746nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 746 to 682nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 746 to 682nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 746 to 682nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 529 to 413nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of thecompositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 529 to 413nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 529 to 413nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 850 to 798nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 850 to 798nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 850 to 798nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 798 to 746nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 798 to 746nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 798 to 746nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 746 to 682nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 746 to 682nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, theenhancer is an upstream enhancer from a Class of Series D sequences, positioned 746 to 682nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 529 to 413nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 529 to 413nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 529 to 413nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series D sequences, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, positioned 232 to 180nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, positioned 232 to 180nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, positioned 232 to 180nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods providedherein, the enhancer is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series E sequences, positioned 232 to 180nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series E sequences, positioned 232 to 180nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series E sequences, positioned 232 to 180nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series E sequences, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series E sequences, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series E sequences, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 84 to 32nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancerand the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 84 to 32nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 84 to 32nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 843 to 753nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 843 to 753nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 843 to 753nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series Fsequences, positioned 84 to 32nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series F sequences, positioned 84 to 32nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series F sequences, positioned 84 to 32nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series F sequences, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series F sequences, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series F sequences, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series F sequences, positioned 843 to 753nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series F sequences, positioned 843 to 753nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence. In one embodiment of any one of the compositions or methods provided herein, the enhancer is an upstream enhancer from a Class of Series F sequences, positioned 843 to 753nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0038] Any one of the constructs provided herein may comprise any one of the enhancer sequences provided herein.

[0039] Any one of the constructs provided herein can comprise any one of the coding sequences, such as for any one of the therapeutics provided herein.

[0040] Any one of the constructs provided herein can comprise any one of the polyadenylation signals provided herein.Any one of the constructs provided herein can comprise any one of the Kozak sequences provided herein.

[0041] Any one of the constructs provided herein can comprise any one of the spacer sequences provided herein.

[0042] In one aspect is a method of administering any one of the compositions or provided herein to a subject. In one embodiment, the subject may be any one of the subjects provided herein. In one embodiment, the administering may be via any mode of administration provided herein. In one embodiment, the administering may for any purpose provided herein.

[0043] In one aspect is any composition or method provided in the Examples.

[0044] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows the potency versus size of upstream enhancer cassettes.

[0045] FIG. 2 shows sequence homologies relative to SEQ ID NO. 1.

[0046] FIG. 3 shows sequence homologies relative to SEQ ID NO. 3.

[0047] FIG. 4 shows sequence homologies relative to SEQ ID NO. 4.

[0048] FIG. 5 shows sequence homologies for Series D sequences.

[0049] FIG. 6 shows the effect of pre-Kozak leaders with core promoter enhancers.

[0050] FIG. 7 shows the potency versus size of upstream enhancer cassettes.

[0051] FIG. 8 shows effects of enhancer set 2.

[0052] FIG. 9 shows sequence homologies for Series E sequences.

[0053] FIG. 10 shows sequence homologies for Series F sequences.

[0054] FIG. 11 shows results from a scan of various constructs, promoter and enhancer combinations.

[0055] FIG. 12 shows the construct from Example 1.

[0056] FIG. 13 shows the construct from Example 2.

[0057] FIG. 14 shows a construct from Example 3.

[0058] FIG. 15 shows a construct from Example 3.

[0059] FIG. 16 shows the construct from Example 5.

[0060] FIG. 17 shows potency enhanacing features by size of feature.

[0061] FIG. 18 shows construct size distribution inclusive of potency enhancing features.

[0062] DETAILED DESCRIPTION OF INVENTION

[0063] Before describing the present invention in detail, it is to be understood that this invention is not limited to particularly exemplified materials or process parameters as suchmay, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting of the use of alternative terminology to describe the present invention.

[0064] All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety for all purposes. Such incorporation by reference is not intended to be an admission that any of the incorporated publications, patents and patent applications cited herein constitute prior art.

[0065] As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the content clearly dictates otherwise. For example, reference to "a molecule" includes a mixture of two or more such molecules or a plurality of such molecules, and the like.

[0066] As used herein, the term “comprise” or variations thereof such as “comprises” or “comprising” are to be read to indicate the inclusion of any recited integer (e.g. a feature, element, characteristic, property, method / process step or limitation) or group of integers (e.g. features, elements, characteristics, properties, method / process steps or limitations) but not the exclusion of any other integer or group of integers. Thus, as used herein, the term “comprising” is inclusive and does not exclude additional, unrecited integers or method / process steps.

[0067] In embodiments of any of the compositions and methods provided herein, “comprising” may be replaced with “consisting essentially of’ or “consisting of’. The phrase “consisting essentially of’ is used herein to require the specified integer(s) or steps as well as those which do not materially affect the character or function of the claimed invention. As used herein, the term “consisting” is used to indicate the presence of the recited integer (e.g. a feature, element, characteristic, property, method / process step or limitation) or group of integers (e.g. features, elements, characteristics, properties, method / process steps or limitations) alone.

[0068] Summary

[0069] The present invention relates, at least in part, to nucleic acid constructs and gene therapy systems comprising enhancer-spacer- Kozak architectures that enable enhanced expression of encoded proteins or peptides. In particular, the invention provides nucleic acid constructs in which one or more enhancer sequences, which can be positioned upstream of a Kozak sequence and separated by a defined spacer region. The constructs can result in increased expression relative to constructs lacking such enhancer elements.

[0070] In certain embodiments, the invention further relates to circular nucleic acid constructs in which the spatial positioning of the enhancer-spacer-Kozak architecture relativeto other regulatory elements, including a polyadenylation signal, for example, can impact expression levels. Unexpectedly, it has been observed that positioning of such enhancer architectures within a defined distal region of the construct results in robust expression, whereas positioning outside of this region can result in significantly reduced, inconsistent, or non-quantifiable expression.

[0071] In one aspect, using an Enhancer-Spacer- Kozak Architecture a nucleic acid construct is provided comprising:

[0072] • a coding sequence encoding a protein or peptide,

[0073] • a Kozak sequence operably linked to the coding sequence,

[0074] • a spacer sequence positioned upstream of the Kozak sequence, and

[0075] • at least one enhancer sequence positioned upstream of the Kozak sequence and separated from the Kozak sequence by the spacer.

[0076] In one embodiment of any one of the compositions or methods provided herein, the enhancer sequence is delivered in cis with the coding sequence and is configured to increase expression of the encoded protein or peptide relative to an otherwise identical construct lacking the enhancer sequence.

[0077] In one embodiment of any one of the compositions or methods provided herein, the spacer sequence may be between 0 and 52 nucleotides in length, including ranges of 0-23 nucleotides or 0-18 nucleotides.

[0078] In one embodiment of any one of the compositions or methods provided herein, the enhancer sequence is positioned within 0-52 nucleotides upstream of the Kozak sequence, including preferred positions within 18-23 nucleotides upstream of the Kozak sequence. The Kozak sequence may comprise a canonical or non-canonical translation initiation sequence, including but not limited to GCCACCATGG or variants thereof.

[0079] In one embodiment of any one of the compositions or methods provided herein, the enhancer sequences may comprise defined sequence motifs, consensus elements, or functional analogs thereof. In one embodiment of any one of the compositions or methods provided herein, the enhancer sequence comprises a GC-rich sequence, a CpG-rich sequence, or a motif of the form C[A / G]GGTT[G / T]G. In one embodiment of any one of the compositions or methods provided herein, the enhancer sequence comprises a sequence having at least 85% identity to one or more sequences selected from:

[0080] • C[A / G]GGTT[G / T]G,

[0081] • GCGAAGCGCGCGGCGGGCGGGAG,

[0082] • CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC,• CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA,

[0083] • GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC,

[0084] • CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG,

[0085] • GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCA GGGCTCAGGATA, or functional variants thereof.

[0086] In one embodiment of any one of the compositions or methods provided herein, multiple enhancer sequences may be present, including combinations of proximal and distal enhancer elements.

[0087] Spacer sequences may be positioned between the enhancer and the Kozak sequence and may influence transcriptional and translational efficiency. In one embodiment of any one of the compositions or methods provided herein, the spacer sequence comprises GTTGGACGCGTCGCTAGC or sequences having at least 85% identity thereto, or other non-coding sequences lacking translation initiation codons.

[0088] In one embodiment of any one of the compositions or methods provided herein, spacer sequences may be selected to maintain appropriate spacing, structural configuration, or regulatory accessibility between the enhancer and the translation initiation site.

[0089] The enhancer-spacer-Kozak architecture described herein can provide increased expression of the encoded protein or peptide relative to constructs lacking the enhancer sequence. In one embodiment of any one of the compositions or methods provided herein, expression is increased by at least 2-fold.

[0090] Also importantly, the present invention demonstrates that certain enhancer configurations are capable of overcoming the inverse relationship between construct size and expression commonly observed in non- viral gene delivery systems. In particular, the inclusion of the enhancer sequence can result in expression levels that exceed those predicted based on construct size alone.

[0091] In a further aspect, the invention provides circular nucleic acid constructs, including plasmid DNA constructs, in which the position of the enhancer-spacer-Kozak architecture relative to other regulatory elements is important for expression. In embodiments, the construct comprises:

[0092] • a coding sequence,

[0093] • a polyadenylation signal downstream of the coding sequence,• and an enhancer-spacer-Kozak architecture positioned elsewhere within the circular construct.

[0094] Further, unexpectedly, it has been observed that the start position of the spacer sequence, relative to the polyadenylation signal, defines an important positional window for functional expression. In one embodiment of any one of the compositions or methods provided herein, the start position of the spacer sequence is located between approximately 2,000 and 7,500 nucleotides downstream of the poly adenylation signal. In one embodiment of any one of the compositions or methods provided herein, the functional window is between 2,031 and 7,271 nucleotides downstream of the polyadenylation signal. Results are shown in FIG. 17.

[0095] Another important feature of the present invention is based on the discovery of a nonlinear and non-obvious dependence of gene expression on the positional architecture of enhancer elements within circular constructs. Specifically, when the enhancer-spacer-Kozak architecture is positioned within the defined positional window, robust and reproducible expression is observed.

[0096] In contrast, when the enhancer is positioned outside of this window, expression is significantly reduced, inconsistent across constructs or conditions, and / or below the lower limit of quantification (LLoQ). This dramatic loss of expression outside the defined positional range demonstrates that the enhancer function can be dependent on long-range spatial organization within the construct, in embodiments, and cannot be predicted based on conventional models of enhancer proximity or promoter activity. These findings establish that the positional architecture described herein is not a result of routine optimization, but rather reflects a previously unrecognized regulatory phenomenon governing gene expression in circular nucleic acid constructs. Results are shown in FIG. 18.

[0097] The constructs of the present invention may further comprise promoters upstream of the enhancer sequence, including viral, mammalian, synthetic, or hybrid promoters. In one embodiment of any one of the compositions or methods provided herein, the enhancer sequence is distinct from and not part of the promoter. Additional regulatory elements may include introns, secondary enhancers, untranslated regions, and other transcriptional or post-transcriptional regulatory sequences.

[0098] The nucleic acids, constructs, and coding sequences of any one of the compositions or methods provided herein may encode any protein or peptide, including secreted proteins. In one embodiment of any one of the compositions or methods provided herein, the encoded protein is selected from:• incretins (e.g., GLP-1, glucagon),

[0099] • fibroblast growth factors (e.g., FGF21),

[0100] • antibodies or antibody fragments, and

[0101] • cytokines, growth factors, or fusion proteins. The encoded protein may be fused to functional domains, including Fc regions or albumin-binding moieties, to enhance stability, half-life, or bio availability.

[0102] The nucleic acid constructs or any composition provided herein may be delivered using viral or non-viral vectors, including lipid nanoparticles, polymeric systems, or other delivery platforms. In one embodiment of any one of the compositions or methods provided herein, the constructs or compositions are administered subcutaneously and localize to subcutaneous tissues, including adipocytes. Expression of the encoded protein may result in systemic distribution and therapeutic effect.

[0103] The present invention provides, at least in part, the identity, sequences, motifs, positioning, and applications of in cis-delivered enhancers that can be used to improve the potency of subcutaneously administered gene therapies. These enhancer elements can be used in combination with both viral and non-viral delivery vectors to achieve enhanced and sustained therapeutic transgene expression following subcutaneous injection or other routes of administration. This advancement expands the utility of gene therapy to new administration routes and supports the development of safer, more effective genetic medicines.

[0104] The present invention presents potency enhancing upstream factors that are effective in adipocyte targeting or subcutaneously localizing gene therapies. Moreover, the identified factors provide an increase in potency that can overcome the reduction in potency mediated by the inclusion of additional DNA into the construct, which is known to be inversely associated with potency for non-virally delivered DNA constructs. Finally, the present invention discloses the beneficial positioning of said potency enhancing sequences and their use with various promoters, Kozak sequences, and Pre-Kozak spacers.

[0105] As previously noted, an increase in genetic cassette size is inversely correlated to potency of gene expression for non-virally delivered constructs. This was generally confirmed by the studies evaluating various upstream enhancers and activators, however, several enhancers and activators containing specific consensus sequences were able to overcome the trend to increase gene expression above the size-productivity curve.For the purposes of this invention the Kozak sequence is defined as a sequence spanning the start codon (e.g., ATG), is 10 nucleotides long and contains the start codon in positions 7 through 9 (1 base). Similarly, for the purposes of this invention the term starting with respect to a sequence that is upstream of another sequence means the last nucleotide of the upstream sequence, i.e., ABCDEFXXX, the sequence ABC starts 4 nucleotides upstream of the sequence XXX.

[0106] Several pre-Kozak spacers were evaluated from 0 to 52, with several spacers of the size 18, 23, and 52. In one embodiment of any one of the compositions or methods provided herein, the enhancer sequence can be a Pre-Kozak leader sequence, or part of a Pre-Kozak spacer and be positioned to start 0-52 nucleotides, or more optionally 0-23 nucleotides, or most ideally 0-18 nucleotides upstream of the start of the Kozak sequence. Said enhancer can have a sequence C[A / G]GGTT[G / T]G (Series A) or optionally CAGGTTGG. Said sequence can be positioned in immediate proximity to the Kozak sequence, i.e., CAGGTGG-KozakfATG] or start up to 52 nucleotides upstream of the Kozak sequence, i.e., such that the terminal G of C[A / G]GGTT[G / T]G is exactly 52 nucleotides away from the initial nucleotide of the Kozak sequence. Sequences homologous to C[A / G]GGTT[G / T]G, which are also part of the Series A sequences can achieve the same functionality for the purposes of this invention.

[0107] Use of said leader across several constructs relative to controls and use of the leader across two constructs with the same promoter indicated increase in the potency of expression by a factor of 3.76 when positioned <52 nucleotides upstream of the Kozak sequence in a given promoter-intron coupling for gene therapy treatments administered to adipocytes in vivo. As such, the present invention provides the utilization of said sequences with gene therapies intended for subcutaneous administration, subcutaneous localization, or adipocyte targeted vectors.

[0108] Similar effects can be enabled using the sequence ACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG (SEQ ID NO: 2, Series A), or >95% analogs TGAAAAAAAGTGATTTCAGGCAG (SEQ ID NO: 9), TGAAAAAAAGTAATTTCAGGCAG (SEQ ID NO: 10), CTGCCTGAAATTACTTTTTTTC (SEQ ID NO: 11), CTGAAAAAAAGTGATTTCAGGCA (SEQ ID NO: 12), CCTGAAAAAAAGTGATTTCAGG (SEQ ID NO: 13), AAATCACTTTTTTTCAGGTTGG (SEQ ID NO: 14), CTGCCTGAAATCACTTTTTTTC (SEQ ID NO: 15), ACCTGCCAGAAATCACTTTTTTTCAG (SEQ ID NO: 16),ACCTGCCAGAAATGACTTTTTTTCAGG (SEQ ID NO: 17), ACCTGCCAGAAATGACTTTTTTTCAG (SEQ ID NO: 18), CTGAAAAAAAGTCATTTCTGGCAGGT (SEQ ID NO: 19), CTGAAAAAAAGTGATTTC (SEQ ID NO: 20), GAAATCACTTTTTTTCAG (SEQ ID NO: 21), ACCTGTCTGAAATGACTTTTTTTCAG (SEQ ID NO: 22), GAGCACCTGTCAGAAATCACTTTTTT (SEQ ID NO: 23), AAAAAAGTGATTTCAGACAGGT (SEQ ID NO: 24), CTGAAAAAAAGTAATTTCTGGCAGGT (SEQ ID NO: 25), AACCTGAAAAAAAGTGATTTCA (SEQ ID NO: 26), AAAAAAAGTGATTTCAGGCAGG (SEQ ID NO: 27), TGAAAAAAAGTGATTTCAGG (SEQ ID NO: 28) (Series A sequences).

[0109] In one embodiment of any one of the compositions or methods provided herein, an enhancer motif GCGAAGCGCGCGGCGGGCGGGAG (SEQ ID NO: 3, Series B) is used with subcutaneously administered, subcutaneously localizing, or adipocyte targeting gene therapies. Said motif can be positioned starting at positions 316-264 nucleotides upstream of the Kozak sequence, or alternatively starting at positions 251-199 nucleotides upstream of the Kozak sequence or a 0 to 52 nucleotide spacer upstream of the Kozak sequence or the 0 to 23 nucleotide spacer upstream of the Kozak sequence or most ideally an 18 to 23 nucleotide spacer upstream of the Kozak sequence.

[0110] Similar potency increasing effects can be obtained with the following >95% analogs (Series B sequences) at the same positions within the genetic cassette:

[0111] GCGAAGCGCGCGGCGGGCGGGAG (SEQ ID NO: 3), GCGAAGCGCGCGGCGGGC (SEQ ID NO: 29), CTCCCGCCCGCCGCGCGCTTCGC (SEQ ID NO: 30), TCCCGCCCGCCGCGCG (SEQ ID NO: 31), GCGCGCGGCGGGCGGG (SEQ ID NO: 32), GCGCGCGGCGGGCGGGA (SEQ ID NO: 33), TCCCGCCCGCAGCGCGCTTC (SEQ ID NO: 34), CGAAGCGCGCGGCGGGCGGGAG (SEQ ID NO: 35), CCCGCCCGCCGCGCGCTTCGC (SEQ ID NO: 36), CCGCCGCGCGCTTCGC (SEQ ID NO: 37), GAAGCGCGCGGCGGGCG (SEQ ID NO: 38), CTCCCGCCCGCCGCGCGCTTC (SEQ ID NO: 39), CGAAGCGCGCGGCGGGCGGG (SEQ ID NO: 40), AGCGCGCGGCGGGCGG (SEQ ID NO: 41), CCCGCCCGCCGCGCGC (SEQ ID NO: 42), TCCCGCCCGCCGCGCGCTTC (SEQ ID NO: 43), CCCGCCCGCCGCGCGCTTCG (SEQ ID NO: 44), CCGCCCGCCGCGCGCT (SEQ ID NO: 45), AAGCGCGCGGCGGGCGGGAG (SEQ ID NO: 46), GAAGCGCGCGGCGGGCGGGA (SEQ ID NO: 47), CCGCCCGCCGCGCGCTTCGC(SEQ ID NO: 48), AGCGCGCGGCGGGCGGG (SEQ ID NO: 49), CGAAGCGCGCGGCTGGCGGGA (SEQ ID NO: 50), GAAGCGCGCGGCGGGC (SEQ ID NO: 51), CGAAGCGCGCGGCTGGCGGGA (SEQ ID NO: 50), CCCGCCCGCCGCGCGCT (SEQ ID NO: 52), GCGAAGCGCGCGGCGGGCGG (SEQ ID NO: 53), CGAAGCGCGCGGCGGGCGGG (SEQ ID NO: 40), CTCCCGCCCGCCCCGCGCTTCGC (SEQ ID NO: 54), CTCCCGCCCGCCGCGCGC (SEQ ID NO: 55), TCCCGCCCGCCGCGCGC (SEQ ID NO: 56), CTCCCGCCCGCCGCGCGCT (SEQ ID NO: 57), TCCCGCCCGCCGCGCG (SEQ ID NO: 31), CCCGCCCGCCGCGCGCTTC (SEQ ID NO: 58), GCGAAGCGCGCGGCGGGCGG (SEQ ID NO: 59), GCGAAGCGCGCGGCGGGCG (SEQ ID NO: 60), GCGACGCGCGCGGCGGGCGG (SEQ ID NO: 61), CTCCCGCCGGCCGCGCGCTTCGC (SEQ ID NO: 62), CGCCCGCCGCGCGCTTCGC (SEQ ID NO: 63), CCGCCCGCCGCGCGCTTCG (SEQ ID NO: 64), CCGCCCGCCGCGCGCT (SEQ ID NO: 45), CCCGCCCGCCGCGCGCTTC (SEQ ID NO: 58), GCGAAGCGCGCGGCGCGCGGGAG (SEQ ID NO: 65), AGCGCGCGGCGGGCGGGAG (SEQ ID NO: 66), GCGAAGCGCGCGGCGGGCG (SEQ ID NO: 60).

[0112] In one embodiment of any one of the compositions or methods provided herein, an enhancer motif CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4, Series C) is used with subcutaneously administered, adipocyte targeting, or subcutaneously localizing gene therapies. Said sequence can be positioned starting at positions 932-840 nucleotides upstream of the Kozak sequence, or alternatively 615-563 nucleotides upstream of the Kozak sequence, or alternatively starting at positions 581-529 upstream of the Kozak sequence, or alternatively starting at positions 295-203 upstream of the Kozak sequence or a 0 to 52 nucleotide spacer upstream of the Kozak sequence or the 0 to 23 nucleotide spacer upstream of the Kozak sequence or most ideally an 18 to 23 nucleotide spacer upstream of the Kozak sequence. Alternatively, Series C sequences can be placed 295-249 upstream of the Kozak sequence or a 0 to 52 nucleotide spacer upstream of the Kozak sequence or the 0 to 23 nucleotide spacer upstream of the Kozak sequence or most ideally an 18 to 23 nucleotide spacer upstream of the Kozak sequence.

[0113] Similar effects can be obtained with the following >95% analogs (Series C sequences) at the same positions within the genetic cassette:

[0114] GTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGG (SEQ ID NO: 67), CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), GTAGATGTACTGCCAAGTAGGAAAGTCCCGTAAGGTCATGTACTGG (SEQID NO: 68), GTAGATGTACTGCCAAGTAGGAAAGTCCCAT (SEQ ID NO: 69), TATGGGACTTTCCTACTTGGCA (SEQ ID NO: 70), TACATGACCTTATGGGACTTTC (SEQ ID NO: 71), AAGTCCCATAAGGTCATGTA (SEQ ID NO: 72), TACATGACCTTATGGGACTT (SEQ ID NO: 73), GGAAAGTCCCTTAAGGTCATGTACT (SEQ ID NO: 74), ATGTACTGCCAAGTAGGAAAG (SEQ ID NO: 75), GAAAGTCCCATAAGGTCATGT (SEQ ID NO: 76), ACTTTCCTACTTGGCAGTACA (SEQ ID NO: 77), TTATGGGACTTTCCTACTTGG (SEQ ID NO: 78), AGGAAAGTCCCATAAGGTCA (SEQ ID NO: 79), TGACCTTATGGGACTTTC (SEQ ID NO: 80), CAAGTAGGAAAGTCCCATAA (SEQ ID NO: 81), ATGTACTGCCAAGTAGGAAA (SEQ ID NO: 82), AAGTAGGAAAGTCCCATACGGTCA (SEQ ID NO: 83), AAAGTCCCATAAGGTCATGT (SEQ ID NO: 84), GTACTGCCAAGTAGGAAAGT (SEQ ID NO: 85), AAGTAGGAAAGTCCCATAAG (SEQ ID NO: 86), ACATGACCTTATGGGACTTT (SEQ ID NO: 87), CTTTCCTACTTGGCAGTAAATCTA (SEQ ID NO: 88), TTCCTACTTGGCAGTACATC (SEQ ID NO: 89), GGGACTTTCCTACTTGGCAG (SEQ ID NO: 90), CCTACTTGGCAGTACATCTA (SEQ ID NO: 91), CATGACCTTATGGGACTTTTCTAC (SEQ ID NO: 92), CCAGTACATCACCTTATGGGACTT (SEQ ID NO: 93), CTTATGGGACTTTCCTACTT (SEQ ID NO: 94), GGACTTTCCTACTTGGCGGTACAT (SEQ ID NO: 95), TGTACTGCCAAGTAGGAAA (SEQ ID NO: 96), TCCCATAAGGTCATGTACT (SEQ ID NO: 97), ACTGCCAAGTAGGAAAGTC (SEQ ID NO: 98), CCATAAGGTCATGTACTGG (SEQ ID NO: 99), AGATGTACTGCCAAGTAGG (SEQ ID NO: 100), AAGTAGGAAAGTCCCATAA (SEQ ID NO: 101), TACTGCCAAGTAGGAAAGT (SEQ ID NO: 102), AAAGTCCCATAAGGTCATG (SEQ ID NO: 103), CCAGTACATGACCTTATG (SEQ ID NO: 104), TTTCCTACTTGGCAGTACA (SEQ ID NO: 105), CTTTCCTTCTTGGCAGTACATC (SEQ ID NO: 106).

[0115] The present invention also provides an enhancer sequence CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA (SEQ ID NO: 5, Series D) for use with subcutaneously administered, subcutaneously localizing, or adipocyte targeting gene therapies. Said sequence can be positioned starting at positions 1166-1050 nucleotides upstream of the Kozak sequence, or alternatively 850-798 nucleotides upstream of the Kozak sequence, or alternatively starting at positions 798-746 nucleotides upstream of the Kozak sequence, or alternatively 746-682 nucleotides upstream of the Kozak sequence, or alternatively 529-413 nucleotides upstream of the Kozak sequence,or a 0 to 52 nucleotide spacer upstream of the Kozak sequence or the 0 to 23 nucleotide spacer upstream of the Kozak sequence or most ideally an 18 to 23 nucleotide spacer upstream of the Kozak sequence.

[0116] Similar effects can be obtained with the following >95% analogs (Series D sequences) at the same positions within the genetic cassette:

[0117] CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA (SEQ ID NO: 5), ACGGTAAATGGCCCGCCTGGC (SEQ ID NO: 107), TGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTA ACG (SEQ ID NO: 108), GCCAGGCGGGCCATTTACCGT (SEQ ID NO: 109), TAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCA (SEQ ID NO: 110), GTTACATAACTTACGGTAAATG (SEQ ID NO: 111), CGTTACATAACTTACGGTAAAT (SEQ ID NO: 112), CATTTACCGTAAGTTATGTAAC (SEQ ID NO: 113), ATTTACCGTAAGTTATGTAACG (SEQ ID NO: 114), GGGGGTCGTTGGGCGGTCAGCC (SEQ ID NO: 115).

[0118] The same size-potency trend was observed with mammalian or human promoters, enhancers, or activators, i.e., the larger the inserted construct, the lower the potency.

[0119] However, some enhancer elements clearly outperformed the trend and can therefore be used to increase potency of expression without reliance on size optimization or in conjunction with total construct size optimization.

[0120] As such, using the following set of enhancers at the predefined positions upstream of the Kozak sequence can increase gene expression by up to 3.89x.

[0121] The present invention additionally discloses the use of an enhancer sequence GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC (SEQ ID NO: 6, Series E) for use with subcutaneously administered, subcutaneously localizing, or adipocyte targeting gene therapies. Said sequence can be positioned starting at positions 232-180 nucleotides upstream of the Kozak sequence or alternatively starting at positions 1179-1127 upstream of the Kozak sequence or a 0 to 52 nucleotide spacer upstream of the Kozak sequence or the 0 to 23 nucleotide spacer upstream of the Kozak sequence or most ideally an 18 to 23 nucleotide spacer upstream of the Kozak sequence.

[0122] Similar effects can be obtained with the following >95% analogs (Series E sequences) at the same positions within the genetic cassette:

[0123] GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC (SEQ ID NO: 6), GGGCGATGTGCGCTCTGCCCACTGACGGGCACCGGAGCC (SEQ ID NO: 116), GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACA (SEQ ID NO: 117),GCGCTGTGCGCTCTGCCCACTG (SEQ ID NO: 118), CAGTGGGCAGAGCGCACAGCG (SEQ ID NO: 119), TGGGCAGAGCGCACAGCGCCC (SEQ ID NO: 120), GCTCTGCCCACTGACGGGCAC (SEQ ID NO: 121), GGTGCCCGTCAGTGGGCACAGCGCA (SEQ ID NO: 122).

[0124] The present invention additionally discloses an enhancer sequence CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG (SEQ ID NO: 7, Series F) for use with subcutaneously administered, subcutaneously localizing, or adipocyte targeting gene therapies. Said sequence can be positioned starting at positions 84-32 nucleotides upstream of the Kozak sequence or alternatively starting at positions 1031-979 nucleotides upstream of the Kozak sequence or 843-753nt upstream of the Kozak sequence or a 0 to 52 nucleotide spacer upstream of the Kozak sequence or the 0 to 23 nucleotide spacer upstream of the Kozak sequence or most ideally an 18 to 23 nucleotide spacer upstream of the Kozak sequence.

[0125] Similar effects can be obtained with the following >95% analogs (Series F sequences) at the same positions within the genetic cassette:

[0126] CACGGCGACTACTGCACTTATATACGGTTCTCCCCCACCCTCGGG (SEQ ID NO: 123), CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG (SEQ ID NO: 7), CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCC (SEQ ID NO: 124), CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGC (SEQ ID NO: 125), CCCGAGGGTGGGGGAGAACCGTATATAAGTGCCGTAGTCGCC (SEQ ID NO: 126), CCCGAGGGTGGGGGAGAACCGTATATAAGTGCGGTAGTCGCC (SEQ ID NO: 127), CACGGAGACTACGGCACTTATATACGGTTCTCCCCCACCCTCGGG (SEQ ID NO: 128), CCCGAGGGTGGGGGAGAACCGTATATAAGTGCCGTAGTCCCCGTG (SEQ ID NO: 129).

[0127] A similar potency enhancing effect can be attained using GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCAGGGCT CAGGATA (SEQ ID NO: 8, Series G), which can be positioned starting immediately upstream of the Pre-Kozak spacer, which can be 0-18 or 0-52 nucleotides in length; or generally Series G sequences below.

[0128] Series G sequences:

[0129] GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCAGGGCT CAGGAT (SEQ ID NO: 130),

[0130] ATCCTGAGCCCTGAAATTGTCAGGTGAATAGTCATGGGAATGGCAGACTCACACGGCACATCC (SEQ ID NO: 131), ATCCTGAGCCCTGGAAGTGTCAGGTGAATAGTCATGGGAAGGGCAGACTCACACG GCACATCC (SEQ ID NO: 132), ATCCTGAGCCCTGAAACTGACAGGTGCAGAGTCATGGGAAGGGCAGACTCGAAA GGCACATCC (SEQ ID NO: 133), GGATGTCCTGTGTGAGTCTGCCCTTCCCATGACTATACGCCTGTCAGTTTCAGGAC TCAGGAT (SEQ ID NO: 134), ATGACTATTCACCTGTCAATTTCAGGGCTCAGGAT (SEQ ID NO: 135), AGTCTTCCTTTCCCATGAATATTAACCGGTCAATTTCA (SEQ ID NO: 136).

[0131] The enhancer sequences can be used with tissue specific or constitutive promoters, or generally viral, mammalian, synthetic, or combination promoters with or without the use of enhancing introns or additional secondary upstream or downstream enhancers. Broad promoter screens that utilize the enhancer sequences described in the present invention demonstrated that the core promoter remains functional when delivered to subcutaneous adipocytes and can drive transgene expression. As such, the sequences described can be used on their own with core promoters and enhancers, or as part of the full promoter sequences described below, upstream of the Kozak sequence separated by a 0-18, 0-23, or 0-52nt spacer.

[0132] A general scan of the various constructs containing enhancer / regulator or promoter combinations is shown in FIG. 11. Promoter sequences combined with various enhancers were evaluated of potency of expression using a reporter gene construct following subcutaneous administration. Consensus motifs or specific sequences utilized with specific promoters promoted an increase in gene expression by nearly two orders of magnitude, suggesting that the evaluated enhancer sequences are highly effective at increasing gene expression in the subcutis.

[0133] Pl CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCATTGACGTCAATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGA GTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTAC GCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTGTGCCCAGTACA TGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTAC CATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCTCCC CACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGC GGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAA GTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCG CGGCGGGCGGGAGTCGCTGCGCGCTGCCTTCGCCCCGTGCCCCGCTCCGCCGCCG CCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGG GCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCTGAGCAAGAGGTAAGGGTTT AAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCCTGA AATCACTTTTTTTCAGGTTGG (SEQ ID NO: 137)

[0134] P2 CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCAT TGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGT GTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCT GGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACT CGAGGCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCTCCCCACCCCCAATTT TGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGGGGGGG GGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGG AGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTTCCTTTTATGG CGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCGGGA GCGGGATCAGCCACCGCGGTGGCGGCCTAGAGTCGACGAGGAACTGAAAAACCA GAAAGTTAACTGGTAAGTTTAGTCTTTTTGTCTTTTATTTCAGGTCCCGGATCCGGT GGTGGTGCAAATCAAAGAACTGCTCCTCAGTGGATGTTGCCTTTACTTCTAGGCCT GTACGGAAGTGTTACTTCTGCTCTAAAAGCTGCGGAATTGTACCCGCGGCCGATCC ACCGGTCCGGAATTCCCGGGATATCGTCGACCCACGCGTCCGGGCCCCACGCTGC GCACCCGCGGGTTTGCT (SEQ ID NO: 138)

[0135] P3 GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAG TTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTA AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAG AACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC GCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGG GTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGG AGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGC GTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGC CATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGT AAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGC GACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCG CGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGC CTGGTCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTC GGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAG CTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACA AAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTAC CGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTT AGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAG ACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTT GAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCT TCCATTTCAGGTGTCGTGA (SEQ ID NO: 139)

[0136] P4 GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAG TTGGGGGGAGGGGTCGGCAATTGATCCGGTGCCTAGAGAAGGTGGCGCGGGGTA AACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAG AACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC GCCAGAACACAGG (SEQ ID NO: 140)

[0137] P5 GACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAG CCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGAC CGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACG CCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCA CTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGA CGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTAC TTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCA GTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACC CCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGG GAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCC ATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCCCTCG AAGCTTACATGTGGTACCGAGCTCGGATCCTGAGAACTTCAGGGTGAGTCTATGG GACCCTTGATGTTTTCTTTCCCCTTCTTTTCTATGGTTAAGTTCATGTCATAGGAAG GGGAGAAGTAACAGGGTACACATATTGACCAAATCAGGGTAATTTTGCATTTGTAA TTTTAAAAAATGCTTTCTTCTTTTAATATACTTTTTTGTTTATCTTATTTCTAATACTT TCCCTAATCTCTTTCTTTCAGGGCAATAATGATACAATGTATCATGCCTCTTTGCACC ATTCTAAAGAATAACAGTGATAATTTCTGGGTTAAGGCAATAGCAATATTTCTGCAT ATAAATATTTCTGCATATAAATTGTAACTGATGTAAGAGGTTTCATATTGCTAATAGC AGCTACAATCCAGCTACCATTCTGCTTTTATTTTATGGTTGGGATAAGGCTGGATTA TTCTGAGTCCAAGCTAGGCCCTTTTGCTAATCATGTTCATACCTCTTATCTTCCTCC CACAGCTCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCACTTTGGCAAAG

[0138] (SEQ ID NO: 141)

[0139] P6 TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTC CGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCC GCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC ATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAA GTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGC CTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTA CGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATG GGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTC CGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGC AGAGCTGGTTTAGTGAACCGTCAGATC (SEQ ID NO: 142)

[0140] P7 CTTGCTAGTGTATGCAATGGTGTCAGCGTTTGGAAGCTGATTATGGGATGGATCCC TGGATATGGCAATCACTAGATGGTCTATCCTTTTGTCACAGCTCCAAATTTTGTCTC TGTAACTCCTTCCATGGGTGTTTTGTTCCCATTTCTAAGAAGGGGCAAAGTGTCCA CACTTTGGTCTTTGTTCTTCTTGAGTTTCATGCGTTTAGCAAATTGTATCTTATATCT TGGGTATTCTAAATGTCTGGGCTAATATCCACTTATCAGTGAGTACATATTGTGTGAGTTCCTTTGTGATTGGGTTACCTCACTCAGGATGATGCCCTCCAGGTCTATCCATTT GCCTAGGAATTTCATAAATTCATTCTTTTTAATAGCTGAGTAGTACTCCATTGTGTAA ATGTACCACATTTCTGTATCCATTCCTCTGTTGAGGGGCATCTGGGTTCTTTCCAGC TTCTGGCTATTATAAATAAGGCTGCTATGAACATAGTGGAGCATGTGTCCTTCTTAC TGGTTGGGACATCTTCTGGATATATGCCCAGGAGAGGTATTGTGGGATCCTCCGGT AGTACTATGTCCAATTTTCTGAGGAACCGCCAGACTGATTTCCAGAGTGGTTGTAC AAGCTTGCAATCCCACCAACAATGGAGGAGTATTCCTCTTTCTCCACATCCTCGCC AGCATCTGCTGTCACCTGAATTTTTGATCTTAGCCATTCTGACTGGTGTGAGGTGG AATCTCAGGGTTGTTTTGATTTGCATTTCCCTGAAGGTCCCTACTATTTATCTAACAT TTTGAATGCAACATTCTTTCCTTTGTACATAGTCATATGCCATGTGCATTAGTAATCT GCTATAATACAGACCCAACGATGAGACGACTCAGACAAAAGAGTGTATTTGTATCT CTTGTGACATCTAGGATATAGGGGAAGAAACACTCCACACAGTTATGCAGGGCTCT CTGTTTTGTTTTGTTTTTAAAGATTTATTTTATTTCATTTATTTTATGTATATAAAATAC ATGAAATGAGTACACTGTAGCTATACTGATGGTTGTGAGCCATCATGTGGTTTCTG GGAATTAGAATTCAGGGCCTCTGCTTGCTCTAGTTGGCTCCAGTTGCTCCAGTCTA AAGATTTATTTATTATTAGATCTAAGTACATTGTAGCTGTCTTCAAACACACCAGAA GAGGGCATAGGATCCCATTACAGATGGTTGTGAGCCACCATGTGGTTGCTGGGATT TGAACTCAGGACCTCTGGAAGAGCAGTCAGTGCTCTTAACTGCTGAGCCATCTCT CCAGCCCTTAGCCTGCTCTCTTATATCATCTATGAGCACCTGTCTATGGTAACAGCA CCACAATGGGCTGGACCTTACCTCCTCAATCATCAAGCAAGAAAACGTCCCATAG GCTTGCCCACAGGGCAGTCTGGTGGGAGCATTTCCCCAACTGATGTTCTCTCCCCA AATGACTTATCTGATACACTGGCCTTCGGAGAAAAGCAAGTCAACACCTCATTGTG ATCCCATTTTACCCAGTCAGAATGTCATAAGAAAACAAATAACATTTTCATAAGAA AATAAACAACAATACATTCTGTCAAGGATGTAGACAGATGGGATGCACTTGATTCA CTGCTGGTGGGAATGATAACTAGTCCAATCTCAGTGGAAGTCAGTCTGGAGTGTTC TCAGAAAATGAAAAAATAGCTGGGCAGTGGTGGCAGATGCCTTTAATCCCAGCAC TTGGGAGGCAGAGGCAGGTGGATTTCTGAGTTTGAGGCCAGCCTTGTCTACAGAG TGAGTTCCAGGACAGCCAAGGCTACACAGAGAAACCCTGTCTCAAAAAACCAAA AAAAAGCCGGACGTGGTGGCGCACGCCTTTAATCCCAGCACTCGGGAGGCAGAG GCAGGCGGATTTCTGAGTTCGAGGCCAGCCTGGTCTACAGAGTGAGTTTCAGGAC AGCCAGGGCTACACAGAGAAACCCTGTCTCGAAAAACCAAAAAAAAAAAAAAA AAAAAAAAAAGGAAGTGAAGAATAGCTGTGGATAACACAGCTTTTCTTTTCTTTA TATTTCAGGCATCAGGGATAGAGGTCAGGTGTCAATGTAAATCACTCTACCACTGA GTTACACTTCTAAATTAAAGACATTTTTCCTTTCTTGAATGCCCAAAAATTTGGAGTACTGCAGGACAGGCTCACTCTTCTGCAGTTAGTGTTATGTCTCAAAATTTGATTTG AGGTTTAGTTGTTTCAGTAAATTGTCTTTTTAAAGTCATGACTAAACAATAATATAC AGTGAAATTTAACCACATTCAGGAAACACTGAGGAAACTCAGGCCTGTGGGGAA ATCTGGCCTTTTGTTTAAGTATCTCACTTCGCATGTAGGCGAGAATTGAGATGTGA ACATGAGCTCCTGAAGGAAAGGACCACGTTTCTGTGGCTGCTTCACTCTGGGCAG TAACACATCTGTCCAGGTAAACCCAGCCTTGCTGAACGTCAATCTCAGCACTTGG GAGGCAGAGGTGAGAGTTTGAGGCCAGTCTGATCTATAGAGCAAGTTCCAGGATA GCTTGGGCTACACTGAAAAAACACTGTCTTGAAAAACAAAACAAAACAAAACAA AACAAAACAAAACAAAACAAAACACCAAAAACCAAAAAAGAAAAAAAAAAAC AGGAAAAGAAAAGAAAAAAATCAAAATAAAACAAAGCCAAAAACAAAGCAAAA AAAAAAACCACCCAGCAAAAAACCAAACCGCCTAGCCTCAAGACATGTGTGGTT GAATGTTTTTCACTTCTAGTCGCTAAGCAAGTGTGTGTTTTTACACAATGCCCTCTG TGGTGAGTGGCGGATTCCCCTGAGAGTTCACCAAATGATAGGCTTTCACAATGCTC CCGGGTGTCTACCAGACCCAGCAAAGTATTGATGTGGTTTTGGGGTGAAAGTCAC TCTGTCTTGTGCAATAGTTAGAATCTGCTGAAACCAGCAGTGTTCCTATATGGGAC AGGGGTCCAGAGCTAACCCGGAGGCTATAACTGAGCAGAGGTGAAGACCACGAG GCATTGGGGAGCGTATGCCCTTTGTGGTCAGAGAGATCTAGCTTCGTGCCTTGGGT CTGTGTCTCTCCCTCTTACTGGCTTCTGGCTTCTTCATTAAGTGGGAGACAACCAC AGGTATCTGTATGGGAAGACTCGACTACCCCTTGACTCAACATTGCTTGTTACTTA CTTTGTACAAGATACTACTTAGTCTAGGGGTTATGGAGCATAACCTCAAGTAGGTA AAGCCCCTGCTCCAGCGTGTTTGCATTCCAGTAAGAAGCGAAAGACAGTAACACA CATACAAAATAAGTAAGAAAATGCAACAACAGCAACAACAACAACACACACACA CAAAGTAAGCAAAACGCTAAGGGAAAGATAGAGAGTGATACAGCTTTGAGTTGCT GTAGTTCTTCTCTCTCCTTTGCTTCATACAGTTTGCTTGGGAAGTGTCCAGGGCCAT GGGGTCACAACTAACAGCCCTTGGAAATGAGCTTGTGTCCTTAATCTTCATGACCT AACGTGATTTCTCTAGAAACATCAGTGCATTAACAGGAAGACAAGATGGAAGATC ATATTTTGGCTCTCCTTCCTTGGTGGGTTGACACTGCTGGTCCTATCCACTAGTAAA AGCATGACTCTTAGGCTCTGTGTGGCCAGTGGAAGGTGGCAGTTGGAGGAAGCA GATGCTTGGCCAGCCTTTGCCTGGGAGCAGTCTAGCTCTGAGTGTCTTATTGGAGC AGCTGCTGGCATCCAGAGTTCTTTTTGGATTCACGATTTAATTCAAAAGCTTTGTG CTCCCGAGAATCAGCTCTGGTCTTTCAAAAATAAGATGTGAGTCCGCCGAGAGGC TCCCAAGGTATTGCCTTGCCAACTGCAAGCCTTTTAGGAGCAGTTTAGTGAGTGGT GACTGCTAGTTGCAGTTGGCTGTTAGCCCAGAGCTAATAATAGATAGAAAAGGTAT ATACTTAAGGAGTCTGGAAACTGAGGTTTATCTACTCACAGAAAATGAGTTTCTAAAAAACTAGCTTGAAACTTACCCAGAAAAATCTTAGAACATGGTTCTCCAATGTCA AGGTAAGTGTTCTGTGACACTGGGCTTGAATTATGTAGGGACCACAGATTTTAGAA TTTGGACCCCTGAACTTGCTTCACACCCCACCAGGAACCTTCCTGTACAACAGCC CTCAGAATTCATCTACATGGTCTTTTCTCAGTATGGGATCCGGTCTAGCAAGTGGA GCACACCTTCTATTGCTTAAAGATTTGTTTATGTATATGGGTATTTTGGCTGCATGCA TATTTGCACACCAAAAGAAGGCAGCGGATCCCATGGAATTACTGTGGGTGCTGGG AATTGAACTCAGGACCTCTGGAAGAATAGCCAGTGCTCTTAACCACTGAGCCATG CCTGCAGTCCATCTATTTTTTATTCTAGTACAGCCCCTCTTCATTCTTACTGAAATAG TAATGCCTGAACCACACAGCTTCACATTTAGTTACAAAGAAAGAGTGGGAGTATC ATGTGACAATTAGTGTTGTTGACTCTCCAGGACAAACTTATGGGAAAGGGAGGTC TCCTGACCCCTGAACAATCATTTTACTTGAGGATAATTTTCATTGCACTCAGAAAC ATGCTGAATTATTGTCCTTACCCTTGCCCCATCTCTTGCTCTGGTAGAGAATGGCCA AAGCCTGGAAACAGGATGGCTTGACAGAAGCTCTACTTGGCTTCCCAGACCCAAG CTGGATTAAACCAGGTTCCCTAAGGAGTCTTAAGGCAGCTGCCAGGAGCAAGGGG CCCACTCATTGGCTATTGGCCTTGACTGGGTTGGCCAATGGTAAGCTGGGGTCTGC CTGTCCCCATGAGTACCAGACTAATGAGACCTGGCCACTTTCTCCTCATTTCTGTCT GTACGATTGTCAGTGGATCTGACGACACCAAAAGGTAAGAACAATTCTATATTCTC GGCTGGCTGGGTATGAATGCAGAATCCCACTTGGGCTGTGTTCAGATTTTGCTCTC TGCAGCAGTGTGAAGGTAGATGTTGAGAAAACTCAGGCCTTGGAAACATGGTTGG GGCAGATAAGCTTTGGGGCTTTTCTTTAACTCTTCAAAGCTCTAAGAAAGAAACA ATAACCTTTCGGAACCCCAACTAAGACACTGATGAAGACCTCCTGGGAGAGTGAG GGCTGGGTAGCCACTGAAGGCTCTCTGGGAGAGGCGAGTATGTAGATGCAGATCT TTGGAGTGGATTCCACTTAGCTATATAGGACATGATGCAGGTCCTGATTGGATGTGC CATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCAGGGCTCAGGATA

[0141] (SEQ ID NO: 143)

[0142] P8 GAATTCCCAGCAAGAATCGTGTAGCTGGAGACTCGCAGAGCCATGCAGATTCCTG GCAAGCCATATGACAAATGCACATTTCACCCAGAGAGAAGGGATTGTAGTCAAGA GGGAAGTTACCACCCAGAGAGCAAATAGAGTTCCCAGATGCTTGCCATTTGTGCT CTCTCACTGGACCAGAGTTCACTGGTGGAAGTGTCACATCTCTACGCTCCCCCAA AAGCTCAGCCCTTCCTTGCCTTGCAACAATCAGCCACCCCTGGATGAACTGCTCA GGCTCTGTCTCTTTAGCAGGGTTGGAGCCCACTGTGGCCTGAGCAGCCTTCTATGG CTTTCTTTCTGTGGTTTTCATGATTTCTGAAACCTTGGGCACCAGAGTATCTGAGAGCCCTTCTTTTCCTTCCCTTCCTTCCTTTATGATTCTCTCCTTTCATCCCTTCTCTTG CTAAACTTCCTTCCTTTTCACTCTCCCGGGTTTCATCTCTGAATCATCTACCATGAG CTATTTCCATTGTTTGCCAGGAGACCCCTGAGTTCCTCCTTCTAGAAGTTCAGGCC AGAGTCAGAACCATAACCACCCACCCACAACTGTAATGGACAAAAATAAATGAAC TGAAACCCCATGATCTATATATAAGTCCAGTCCAAGGTTATACCCTGAAAGGGTGG TGATTACATACATTTTACTTATTAAGTTCCTTTTTATGATCAGGGGCTCAGGTTACAG GCCACTGGGGGACTCAGAGTGCCTAGGATTATTGGCAGAGCTGCTCCAATGGCTG TTTCCTTTCTCTGGAAACCCACACAAGCTCTTTCTCCTACTAAACTATCACCTTTCA CATGGTGGTGGCCTGACGTCTACTTATAGCACCCTTAAGCAGTTCATACATGTCAC CCCCTTGCTAAATGTTTTCCCGTAGTACCCTGAGGTTCTTAAGATCTTTTCTGCTTT GTTTAGATTTTGGTTTTGGTTTTTAATCAAGACAGGGTTTCTCTGGCTGTCTTGGAA CTCTGTAGATCAGGCTGGCCTCTAAATCAAGACATCCACCTCCCTCAGATGCGTCA CCACTTTCCAACTGGTTGTTAAAATCTTTACGCCCTGATAGTGATCTCTGCAGCCCT AACCATCCTGTCTTAGGTATATTTAAGATATTAAATATCTTCAAATATCAGGCCTGCC CTGGCTCAGCTCTGAGATTCTGAGATATGTCCTCAAGCCCCACATCCCTGAAGCAA AGCCAGGCTGTTCCCATTGTAGACCATTCTCCACGGCTCCGCTGTGTCAGGTGTTT GTTTGTTTATTTGTTTTTATTTGTTTTCTGAATCTTTTAAAAAATTTAACATGTAACA TCTTTCTTATATCAGAGCATCACCATGTACTAAGCACAACTGGCACTTATTAGGGAT TTAATATCTTCTTTGCATTTAGCTCTATTCCTAGAAAGTAAATTATATATGTGCACAG TCTTAAAATTATATAAAATTCAGGCATTTGAGATTGGTAAAGGTAATAAGACACAA ATACAAAGAAGAGAACAAATGTGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT GTGTGTATTGGCAGGGGTTACTTCTGATGATGGTGCGGCTGGCCTGTCGCTAAGTT CTCTGCTTTTTCTGGTAGAATTTCACCTTTGCTTCCAGTTAGTTCCTGATGGGTTTG CTATATTAAATGAAAACCAAGTAGGTCACAGTTTATATTCAGAGAGCACTTTGCCAT GCCCCTCCCCCACCGTGGGTCTTTGCTTGCACACCCTGAACTGTGTGTGGAGAGC TTCTTTTACGAGCAGGAAGGCAAATGAAGAAGTTACCTAAGAGCCGTCAAGGCGC TCACAGTCTGTCTTGGTCACTGCCCTTTACCCCAGGCTTACTCACTCCCTGCAAAA CTGTTGCTATTTTGAGGTCAAAGAGTCAATACTCAGTCATTGTAACCATACATGCA AAGAAGAACATACTGGCCTAGCTGGATAGGGGACCCAGAACAGTTCTCATGGTAA GTGATCCCAAGAGCATGTGCCTACATTTTCTGTTAAGGGCTCATCTTACAATTGCTA ACAAACACCCAAATGCACTTAGAAATTGAGCAGTAACAAGGGAAGTTTGCCTCCA CACAAAGGAAGTTGCTCTTCCAAAGGGGAGCCTGGGCATGAACCCTCACCTTAGC TGGTCTGTACAAGCTGAAAACTCTCCCTGCCACTGAGACCTCGTCATTACTCTTTA TCATCCGGACAGGGATGTTTCCTCATTAATTAAAAATTGTCAGAAATACCATTGTCATTTCCTCCAAAAGAAATAAACACAGGCAAAGGTTAGAAGGATGCATTCCATAGAG GCTGCCCATTTAGGAGCAAAGTGCAAGGCAAACAGCCTGGACCAGGGTGCCTGC CCTGTCAGCCCTGAGATTCTGAGATGTGACCTCAAGCCCCACATCCCCAAAGCAA AGCCAGGCCTTTCCCATTGCTGACCCGTCCCCACAGATCTGAGGAAATATTCAGCC TGCTGTGTCCTTGTTGTTGTTGTGGAGCATCCTGGTTCTTTTCTAATTTTTAATTTTG AGACACACTCATCGTTAAATGGACTAGGATGGCATTGAACTCACTCTGAGGCTCA GGCAGGCCTTGAACCTACATGATTCTCCTGACTCAGTCTCCTGTGGTGTTTCTTTG TTTTGTTTTGCTTTGGAATTCTAACCTGGTCAATTAAGATTCCCTTGGTGTATTTGAT TAGATATCTGATCATTGACATAAACCCACAACCTTTGATCTGCGTAAATTTAGAACT TGCAATACATTTCAGAAATGGAATGAGGGACATATTTTGGATTGCGACCCATTTTTA AGGGGCCTGTAAAAATCAATACTGCATGGTTATTTAGGAATGGGAAGAGTAAGGCT TAACTTTTAATTTAATTGAATCTGTGCACTACATTCCTGAGCAATGGGCTGCATGCA TTTTAATAAATTGAATATTTGAAATTGTAAGTCTAGGCCACTATAGACAGTACTCAC AGGCAGGCGCAGGCAGATCTCTGTGAGCTAGAGACCAGCCTGGTCTAGGTAGTGA GTTCTAGGACTACCAGGGCTGTGTAGAGAGACACTGTCTAAAATAAATAAGTTTAG GCCACTTTAAAATGTCATTATTTATTTTGTTATAATTCGTGAGATAACACTATTCTAA CAAAAGAGACATTGAGACTAAGAATCTCTAAGAGAGTCTTTATGTTCCCAAATTCA AACCACCAAACACCCTACTGCAGTATTCATAAAATAAAAACTCAAGATAAGAGGG TCAAAGGGTGTCCCAAGGTAATTGTCTCCTCCACAATGAGGTAAATCCATACGGAA TAATAGGGGGAAGTTCAATGCATTAGCTTTTAACAGTCAAAACAGGAACGTTTAA AATACTCTGTTCATAGTTAAAAATAATTTGTACTCTAAGTCCAGTGATCATTGCCAG GGAGAACCAAAGTTGAGAAATTTATATTAAAAACATGACTCAGAGGAAAAAATAC AGGGTCTGGTCATGAAGGAAATGATCTGGGGTCATCCCCCATTGGTCACTCCTCCA GTCACATGGTTGGGACATCTTTAAAAGCGAGTTCCCTGGACTCAGGAGGCACATA GCACCTTCCCCATCCTGCAGCCTTTCTCACCTGGAAGAGAACTCCTTGAAGGCTTA CAAA (SEQ ID NO: 144)

[0143] P9 GAATTCCAGCAGGAATCAGGTAGCTGGAGAATCGCACAGAGCCATGCGGATTCTT GGCAAGCCATGCGACAAAGGCAGAAATGCACATTTCACCCAGAGAGAAGGGATT GTAGTCAGCAGGAAGTCACCACCCAGAGAGCAAATGGAGTTCCCAGATGCCTGA CATTTGCCTTCTTACTGGATCAGAGTTCACTAGTGGAAGTGTCACAGCCCAAACAC TCCCCCAAAGGCTCAGCCCTTCCTTGCCTTGTAACAATCAAGCCGCTCCTGGATGA ACTGCTCCGCCCTCTGTCTCTTTGGCAGGGTTGGAGCCCACTGTGGCCTGAGCGACTTCTATGGCTCCCTTTCTGTGATTTTCATGGTTTCTGAGCTCTTTTCCCCCGCTTTA TGATTTTCTCTTTTTGTCTCTCTCTTGCTAAACCTCCTTCGTATATGCCCTCTCAGGT TTCATTTCTGAATCATCTACTGTGAACTATTCCCATTGTTTGCCAGAAGCCCCCTGG TTCTTCCTTCTAGACTCGAGATCTGCGATCCATTTGTAACAAAAACTCATTATTTAC AGATGAGAAATTTATATTGTCAGCGTAATATCTGTGAGGCTAAACAGAGCTGGAGA GTATATAAAAGCAGTGCGCCTTGGTGCAGAAGTACAGAGCTTAGGACACAGAGCT AGCTGCAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGA CAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAGACTCTTG CGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCACA GGT (SEQ ID NO: 145)

[0144] PIO GTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGC AAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCC AGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCG CCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCC CCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGA GCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAA (SEQ ID NO: 146)

[0145] The present invention also provides therapeutic gene therapy formulations designed for the treatment of human and veterinary pathologies. These genetic elements disclosed in the present invention can be optimized for vectors mediating subcutaneous administration, adipocyte targeting, or subcutaneous localization, and can be used to drive systemic or distal therapeutic effects through the expression of secreted therapeutic proteins or peptides.

[0146] The core of the invention lies, at least in part, in a nucleic acid delivery vector that targets adipocytes and / or localizes to the subcutaneous space, and is primarily designed for the subcutaneous administration of DNA. Generally, a therapeutic goal is to produce secreted proteins or peptides that mediate effects at distant sites from the injection site. Each therapeutic cassette can include an upstream enhancer element delivered in cis (on the same DNA strand) and positioned upstream of the Kozak sequence with a defined spacer region.

[0147] These spacers utilized upstream of the Kozak sequence may range from 0 to 18 nucleotides in length, 0 to 23 nucleotides, or 0 to 52 nucleotides, and can be positionedimmediately upstream of the Kozak consensus sequence, which can be a 10 nucleotide sequence, as an example GCCACCATGG (SEQ ID NO: 147), with the ATG serving as the start codon.

[0148] The invention discloses multiple enhancer sequences, including the motif C[A / G]GGTT[G / T]G or ACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG (SEQ ID NO: 2) or generally enhancers from Series A, GCGAAGCGCGCGGCGGGCGGGAG (SEQ ID NO: 3) or generally enhancers from Series B, CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4) or generally enhancers from Series C, CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA (SEQ ID NO: 5) or generally enhancers from Series D, GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC (SEQ ID NO: 6) or generally enhancers from Series E, and CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG (SEQ ID NO: 7) or generally enhancers from Series F, each placed at varying distances upstream of the Kozak site with defined spacer lengths. Said enhancer sequences can be used upstream of the Kozak site to drive a subcutaneously administered, subcutaneously localizing, or adipocyte-targeting gene therapy or can be positioned within their preferred locations upstream of the Kozak sequence driving expression of the therapeutic transgene.

[0149] Defined spacer sequences include GTTGGACGCGTCGCTAGC (SEQ ID NO: 148) and sequences with >85% identity, GTCCACTCCCAGTTCAATTCACTGTGCACCGGTCGTTGGACGCGTCGCTAGC (SEQ ID NO: 149), and AAGCTGTTGGACGCGTCGCTAGC (SEQ ID NO: 150).

[0150] The encoded therapeutic proteins or peptides include generally secreted proteins or proteins that can be secreted and mediate therapeutic effect, but are not limited to, incretins, antibodies, human secreted proteins, antibody fragments, and fusion proteins. The invention also encompasses proteins from diverse signaling families such as fibroblast growth factors, TGF-p, TNF, interleukins and their receptor antagonists, interferons, CSFs, chemokines, VEGFs, EGFs, HGFs, PDGFs, IGFs, BMPs, GDNFs, neurotrophins, GDFs, Wnts, hedgehogs, TGF-a, RELMs, angiopoietins, galectins, sFRPs, cystatins, serpins, cytokines and antagonists, defensins , cathelicidins, lectins, prolactin / GH family proteins, gastric peptides such as GLP-1, glucagon, amylin, and fusion forms with albumin, Fc-binding peptides, or globulin-binding peptides.The nucleic acid, such as DNA, can be of any structural form including circular or linear, single or double stranded, covalently closed, chemically modified, DNA / RNA hybrids, or DNA conjugated to peptides / small molecules.

[0151] The delivery vectors intended for the use with the genetic cassettes and enhancers disclosed in this invention are generally vectors delivering nucleic acids, such as DNA, in a manner that positions some or ideally most of the nucleic acids in the subcutaneous space or are subcutaneously administered vectors or are adipocyte targeting vectors and include a range of non-viral options such as lipid nanoparticles, liposomes, micelles, carbon nanotubes, nanoemulsion droplets, bilayer sheets, polyelectrolytic complexes, polymeric nanoparticles, dendrimers, and various polymers and biopolymers. Other formulations include PEI complexes, solid lipid nanoparticles, exosomes, cell-penetrating peptides, cationic emulsions, inorganic particles like calcium phosphate, silica, metallic, ceramic, DNA nanostructures, and naked plasmid DNA, among others.

[0152] Vectors may be functionalized with peptides, polymers, saccharides, antibodies, or proteins, or used in combinations. The delivery system may also include viral vectors such as adenovirus, lentivirus, retrovirus, HSV, MVA, or CMV, and additional viruses across numerous viral classes.

[0153] Administration routes include subcutaneous injection, intravenous injections targeting adipose tissues, subcutaneous infusions, and delivery through autoinjectors, patches, microneedles, and related devices.

[0154] Target pathologies include a wide spectrum of diseases encompassing cardiovascular, metabolic, respiratory, neurologic, psychiatric, gastrointestinal, oncologic, autoimmune, infectious, dermatologic, urologic, and reproductive disorders. A subject as herein may have any one or more of the pathologies described herein.

[0155] Together, this invention provides a comprehensive framework for the development and deployment of subcutaneously administered gene therapy systems utilizing precise upstream enhancer-spacer architectures to optimize gene expression and therapeutic protein production for a wide array of pathologies.

[0156] The pathologies targeted by these formulations include, but are not limited to:

[0157] • Metabolic and endocrine diseases such as type 1 and 2 diabetes, obesity, hyperlipidemia, hypothyroidism

[0158] • Cardiovascular conditions including hypertension, coronary artery disease, heart failure

[0159] Respiratory diseases such as COPD, asthma, pulmonary fibrosis• Neurological and psychiatric disorders including Alzheimer’s, Parkinson’s, epilepsy, depression, schizophrenia

[0160] • Autoimmune and monogenic conditions

[0161] • Infectious diseases such as HIV, tuberculosis, malaria, hepatitis, and COVID- 19 • Oncologic indications such as breast, prostate, colorectal, and pancreatic cancer • Musculoskeletal and dermatologic disorders such as rheumatoid arthritis, psoriasis, and acne

[0162] • Gastrointestinal and reproductive diseases such as IBD, endometriosis, and uterine fibroids

[0163] • Or other human or veterinary pathologies.

[0164] The disclosed gene therapy formulations can allow for improved expression control through cell-type- specific or local-tissue-specific enhancer motifs and optimized spacer sequences, enabling effective and durable protein expression in target tissues. This system can be particularly effective for secreted proteins requiring sustained systemic therapeutic levels following localized DNA delivery.

[0165] The aforedescribed genetic elements are most optimally utilized with non-viral delivery vectors, in some embodiments. Some examples of said non-viral delivery vectors include: Lipid nanoparticles (LNPs), liposomes, lipid micelles, carbon nanotubes, nano emulsion droplet, lipid bilayer sheet, polyelectrolytic complex, polymeric nanoparticles, dendrimers, polyethyleneimine (PEI)-based complexes, bioresorbable polymeric nanoparticles such as poly(lactic-co-glycolic acid) (PLGA) nanoparticles, solid lipid nanoparticles, exosomes, micelles, cell-penetrating peptides, cationic emulsions, calcium phosphate nanoparticles, silica nanoparticles, metallic nanoparticles, ceramic nanoparticles, DNA nanostructures, and naked plasmid DNA, or combinations or functionalized derivatives thereof.

[0166] Lipid nanoparticles used for the delivery of genetic cassettes that incorporate sequences described in the present invention can contain no ionizable lipids, multiple ionizable lipids, phospholipids, amphiphilic lipids, conjugated lipids, peptides, proteins, monoclonal antibodies, antibody fragments, DNA, RNA, sterols, structural lipids, polymers, oligomers, polysaccharides, monosaccharides, disaccharides, or surfactants, buffers, stabilizers, antioxidants, or more specifically one or more of bile acids, sphingomyelins, sphingoid bases, gangliosides, glycosphingolipids, ceramides, triacylglycerols, diacylglycerols, monoacylglycerols, isoprenoids, polyprenols, saccharolipids,glycerophosphocholines, glycerophosphoethanolamines, glycerophosphoserines, glycerophosphoglycerols, glycerophosphoinositols, glycerophosphophates, cardiolipins, oxidized glycerophospholipids, thromboxanes, prostaglandins, octadec anoids, lipoxins, leukotrienes, isoprostanes, eicosandoids, fatty esters, fatty ethers, fatty ether-esters, fatty amides, fatty alcohols, fatty aldehydes, fatty acids and conjugates thereof, docosanoids, C2 Ceramide- 1 -phosphate, (2S,3R,4E)-2-Amino-4-tetradecene-l,3-diol, Azido-erythro-sphingosine, Sphingosine- 1 -phosphate (dl6: 1), Sphingosine- 1 -phosphate (dl7: 1), Sphingosine- 1 -phosphate (dl8: 1), N-Butyroyl Phytosphingosine, N-Boc-erythro-sphingosine, D-erythro Lysosphingomyelin (dl8: 1), C24:l Ceramide, C2 to C22 Dihydroceramide, Omega-azido-C6 Ceramide, C16 Sphingomyelin (dl8: 1 / 16:0), 1,2-Dioleoyl-sn-glycerophosphoethanolamine (DOPE), DOPC, ALC-0159, Stearic acid, Nonadecanoic Acid, Arachidic acid, Heneicosanoic acid, Docosanoic acid, Tricosanoic acid, Tetracosanoic acid, 10-Undecenoic acid, 11-Dodecenoic acid, 12-Tridecenoic Acid, Myristelaidic acid, 14-Pentadecenoic acid, 10(Z)-Pentadecenoic acid, 10-Trans-pentadecenoic acid, Palmitelaidic Acid, cis-10-Heptadecenoic acid, Trans- 10-Heptadecenoic Acid, Cis-Vaccenic acid, Trans-Vaccenic acid, Elaidic acid, Ricinoleic acid, Ricinelaidic acid, Petroselinic acid, Trans-Petroselinic Acid, lOZ-Nonadecenoic acid, 10(E)-Nonadecenoic Acid, Delta 7 cis nonadecenoic acid, 7-Trans-Nonadecenoic, (Z)-Icos-ll-enoic acid, trans- 11 -Eicosenoic acid, 8(z)-eicosenoic acid, cis-5-Eicosenoic acid, 12(Z)-Heneicosenoic acid, Erucic acid, 13(E)-Docosenoic Acid, (14Z)-14-tricosenoic acid, Nervonic acid, Linolelaidic acid, 9Z,11Z-octadecadienoicacid, (10z,12z)-octadeca-10,12-dienoic acid, (10Z,13Z)-10,13-nonadecadienoic acid, ll(Z)14(Z)-Eicosadienoic Acid, 12(Z)15(Z)-Heneicosadienoic Acid, 13,16-Docosadienoic acid, (13Z,16Z), alpha-Linolenic acid, Gamma-Linolenic acid, ll(Z)14(Z)17(Z)-Eicosatrienoic Acid, Docosatrienoic Acid, Adrenic Acid, Eicosapentaenoic Acid, Docosapentaenoic Acid, all-cis-47101316-Docosapentaenoic Acid, 306Oi9-cis2, BAMEA-O16B, Al-28, C13-113-tri-tail, C12-113, C13-113-tetra-tail, 1014, C3-K2-E14, OC2-K3-E10, 98N12-5, G0-C14, C12-SPM, C14-SPM, cKK-E12, OF-02, OF-C4-Deg-Lin, 246C10, IC8, C12-200, BP Lipid 432, BP Lipid 103, BP Lipid 124, Lipid A4, C14-4, PPZ-A10, TT3, FTT5, AA-T3A-C12, MVL5, C13- 112-tri-tail, C13-112-tetra-tail, BP Lipid 375, BP Lipid 374, BP Lipid 373, BP Lipid 372, 9A1P9, iPhos-lipidl, iPhos-lipid3, iPhos-lipid4, Dihexadecyl Phosphate, Lipid Catechol, DLPA, DMPA, DPPA, DSPA, 18:1 PA, 1,2-Dioleoyl-sn-glycero-3-PA (ammonium salt), l-Palmitoyl-2-01eoyl-sn-glycero-3-PA, 14:0 Lyso PE, 16:0 Lyso PE, 18:0 Lyso PE, 18:1 Lyso PE, l,2-Didecanoyl-Sn-Glycero-3-Phosphoethanolamine, l,2-Dilauroyl-sn-glycero-3-PE, DMPE, l,2-Dipalmitoyl-sn-glycero-3-PE, 1,3-DPPE, 4ME 16:0 PE, POPE, l-Stearoyl-2-01eoyl-sn-glycero-3-PE, l-Stearoyl-2-Linoleoyl-Sn-Glycero-3-Phosphoethanolamine, 14:0 Lyso PC, 16:0 Lyso PC, 18:0 Lyso PC, 1-Palmitoyl-d9-2-hydroxy-sn-glycero-3-PC, l-Palmitoyl-d3-2-hydroxy-sn-glycero-3-PC, 18:1 Lyso PC, rac-3-Hexadecanamido-2-methoxypropan-l-ol Phosphocholine Monohydrate, 2-Arachidonoyl-sn-glycero-3-phosphocholine (>90%), DHPC, 08:0 PC, DDPC, DLPC, DMPC, MPPC, MSPC, PLPC, PMPC, DPPC, l-Palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine, 17:0 PC, SMPC, SPPC, Distearoylphosphatidylcholine (DSPC), 19:0 PC, DAPC, 16:0 Diether PC, PDME, 4ME 16:0 PC, DEPC, l-01eoyl-2-Palmitoyl-sn-glycero-3-PC, POPC, SOPC, PTPC, SDPC, 22:6 (Cis) PC, l-Palmitoyl-2-(Propargylacetyl)-Sn-Glycero-3-Phosphocholine, SM-102 N-oxide, ALC-0315 N-oxide, Hexadecanedioic Acid Mono-L-carnitine Ester Chloride, Octadecanedioic Acid Mono-L-camitine Ester Chloride, TAP (14:0), 16:0 TAP, 18:0 TAP, DGTS (l,2-dipalmitoyl-sn-glycero-3-0-4'-[N,N,N-trimethyl]-homoserine), 18:1 TAP (l,2-Dioleoyl-3-trimethylammonium propane or DOTAP, MS Salt), DC-6-14, 12:0 EPC (Cl Salt), 14:0 EPC (Cl Salt), 16:0 EPC (Cl Salt), 18:0 EPC (Cl Salt), 14:1 EPC (Tf Salt), 18:1 EPC (Cl Salt), 16:0-18:1 EPC (Cl Salt), l-Palmitoyl-2-arachidoyllecithin, 18:0 DDAB, DOTAP, DOTMA, DODAC, DORI, DOBAQ, DOSPAHC1 salt, 113-O12B, 113-O16B, 14:0 DAP, 16:0 DAP, 304013, 306-N16B, 306-O12B, 306-O12B-3, 3060il0, 4A3-SC8, 503013, 80-O16B, 93-0170, 93-O17S, , A12-Iso5-2DC18, A18-Iso5-2DC18, AA3-DLin, ALC-0315, ATX-001, ATX-100, CKK-E15, CL1, DLin-DMA, DLin-MC3-DMA, DLin-KC2-DMA, D-Lin-MC2-DMA, D-Lin-MC3-DMA, D-Lin-MC4-DMA, DODAP (18:1), DODMA, DOG-IM4, IAJD249, IAJD93, L13, L14, L15, L16, L2, L3, L319, L9, Lipid 10, Lipid 14, Lipid 16, Lipid 2, Lipid 23, Lipid 29, Lipid 5, Lipid 8, Lipid A6, Lipid A9, Lipid AX4, Lipid C24, Lipid ID-45, Lipid R6, LP01, NT1-O14B, OF-Deg-Lin, RCB-4-8, RM 133-3, RM 137-15, SM-102, SSPalmM, SSPalmO-Phe, TCL053, YSK05, 11-A-M, 1-A-N, Cholesterol, Campesterol, Beta-Sitosterol, Brassicasterol, Ergosterol, DHE (Dehydroergosterol), Stigmasterol, Fucosterol, DC-Cholesterol HC1, OH-Chol, OH-C-Chol, HAPC-Chol, MHAPC-Chol, DMHAPC-Chol, DMPAC-Chol, Cholesteryl chloroformate, GL67, Cholesteryl isovalerate, Cholesteryl Acetate, Cholesterol Butyrate, Cholesterol valerate, Cholesterol Hexanoate, Cholesteryl heptanoate, Cholesteryl caprylate, Cholesterol Pelargonate, Cholesterol decanoate, Cholesteryl undecanoate, Cholesterol Laurate, Cholesteryl Tridecanoate, Cholesteryl Myristate, Cholesteryl Pentadecanoate, Cholesteryl Palmitate, Cholesteryl Heptadecanoate, Cholesteryl Stearate, Cholesteryl nonadecanoate, Cholesteryl Arachidate, Cholesteryl Heneicosanoate, Cholesteryl Behenate, Cholesteryl Tricosanoate, Cholesteryl Lignocerate, Cholesteryl Myristoleate, CholesterylPalmitoleate, Cholesteryl Oleate, Cholesteryl 11-Eicosenoate, Cholesteryl Erucate, Cholesteryl Nervonate, Cholesteryl Petroselinate, Cholesteryl Vaccenate (CIS), Cholesteryl Linoleate, Cholesteryl 11-14 Eicosadienoate, Cholesteryl Alpha Linolenate, Cholesteryl Gamma Linolenate, Cholesteryl 11-14-17 Eicosatrienoate, Cholesteryl Arachidonate, Cholesteryl Eicosapentaenoate, Cholesteryl Docosapentaenoate, LC10, Cholesteryl Hemisuccinate, (3B,5B)-3-Hydroxycholan-24-oic acid, Alkyne Cholesterol, 27-Alkyne Cholesterol, E-Cholesterol Alkyne, Biotin-Cholestero, Glucosamine Cholesterol, Cholesterol-Doxorubicin, Cholesterol-Undecanoate-Glucose Conjugate, Cho-es-Lys, Dios-Arg (trifluoroacetate salt), 2H-Cho-Arg (trifluoroacetate salt), Cho-Arg (trifluoroacetate salt), or their derivative.

[0167] Moreover, the aforedescribed genetic elements may be optimally utilized with viral vectors or recombinant viral vectors, or combinations of non-viral and viral vectors within one or more formulations. Such viral vectors include adenovirus, adeno-associated virus (AAV), Alphacoronavirus, Alphaherpesvirus, Alpharetrovirus, Alphavirus, Anellovirus, Astrovirus, Avulavirus, Betacoronavirus, Betaherpesvirus, Betaretrovirus, Betaretrovirus, Bomavirus, Bunyavirus, Calicivirus, Circovirus, Coxsackievirus, Cytomegalovirus, Deltacoronavirus, Deltaretrovirus, Dengue virus, Ebolavirus, Enterovirus, Filovirus, Flavivirus, Gammacoronavirus, Gammaherpesvirus, Hantavirus, Hepacivirus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, Herpes simplex virus, Human immunodeficiency virus (HIV), Human papillomavirus (HPV), Influenza virus, Lentivirus, Lyssavirus, Marburgvirus, Measles virus, Metapneumovirus, Mumps virus, Norovirus, Orthohantavirus, Orthomyxovirus, Parainfluenza virus, Parechovirus, Picomavirus, Poliovirus, Polyomavirus, Rabies virus, Reovirus, Respiratory syncytial virus (RSV), Retrovirus, Rhinovirus, Rotavirus, Rubivirus, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Simian foamy virus, Tenuivirus, Togavirus, Varicella-zoster virus, Variola virus (Smallpox virus), Vesiculovirus, West Nile virus, Yellow fever virus, Zika virus.

[0168] Genetic elements and the derived therapeutic formulations can be utilized for subcutaneous, intramuscular, intravenous, intrathecal, intracerebroventricular, intradermal, topical, intraperitoneal, intra-arterial, intrap ancreatic, epidural, intra- articular, intraosseous, intracardiac, or intravitreal administration. Alternatively, the formulations may be administered locally via an injection, preferably into a local fat pad or tissue intended to be targeted by the therapeutic treatment or tissue intended to be used as the therapeutic producing tissue of interest.The principles described herein are applicable across a wide range of nucleic acid constructs, delivery systems, and therapeutic applications. Variations in sequence identity, enhancer composition, spacer length, and construct design may be employed without departing from the scope of the invention, provided that the functional architecture and positional relationships described herein are maintained.

[0169] For the purposes of this invention nt refers to nucleotides and bp refers to base pairs, nucleotides may define coordinates in both single stranded and double stranded genetic cassettes and are only counted on one of the two strands of the genetic cassette.

[0170] It should be understood that within the scope of this invention the formulation, materials, active agents, active ingredients, moieties, small molecules, drug product compositions, or methods of use may be varied by one skilled in the art, to the extent that the structures described herewithin perform the desired function and remain within the scope of the present invention. Various parts, components or characteristics may be used in combination, with or without modification by someone skilled in the art to achieve the desired functionality of the aforedescribed formulation.

[0171] Moreover, all individual features and methods of use described herein, and each and every combination of two or more of such features and methods of use, are included within the scope of the present invention provided that these features and methods of use in such a combination are not mutually inconsistent. It is understood that certain portions or combinations of such portions can be varied by someone trained in the art while still achieving the main goal of the invention.

[0172] Finally, it is understood that the specific ranges provided in the current invention are not restrictive and are for example purposes only, values outside of the specified ranges may be used to achieve the goal of the invention without modification to the proposed mechanistic principles.

[0173] EXAMPLES

[0174] Example 1

[0175] A glucagon (GLUC) peptide is vectorized with a fragment crystallizable region for enhanced half-life and bioavailability. The therapeutic transgene components and vector are shown below.>GLUC MKSIYFVAGLFVMLVQGSWQRSLQDTEEKSRSFSASQADPLSDPDQMNEDKRHSQG TFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAKRHDEFERHAEGTFTSDVSSYLE GQAAKEFIAWLVKGRGRRDFPEEVAIVEELGRRHADGSFSDEMNTILDNLAARDFIN WLIQTKITDRK (SEQ ID NO: 151)

[0176] >GLUC nucleotide ATGAAAAGCATTTATTTTGTGGCGGGCCTGTTTGTGATGCTGGTGCAGGGCAGCTG GCAGCGCAGCCTGCAGGATACCGAAGAAAAAAGCCGCAGCTTTAGCGCGAGCCA GGCGGATCCGCTGAGCGATCCGGATCAGATGAACGAAGATAAACGCCATAGCCAG GGCACCTTTACCAGCGATTATAGCAAATATCTGGATAGCCGCCGCGCGCAGGATTT TGTGCAGTGGCTGATGAACACCAAACGCAACCGCAACAACATTGCGAAACGCCAT GATGAATTTGAACGCCATGCGGAAGGCACCTTTACCAGCGATGTGAGCAGCTATCT GGAAGGCCAGGCGGCGAAAGAATTTATTGCGTGGCTGGTGAAAGGCCGCGGCCG CCGCGATTTTCCGGAAGAAGTGGCGATTGTGGAAGAACTGGGCCGCCGCCATGCG GATGGCAGCTTTAGCGATGAAATGAACACCATTCTGGATAACCTGGCGGCGCGCG ATTTTATTAACTGGCTGATTCAGACCAAAATTACCGATCGCAAA (SEQ ID NO: 152)

[0177] >2XGGGGS spacers

[0178] GGGGSGGGGS (SEQ ID NO: 153)

[0179] >2XGGGGS spacers nucleotide

[0180] GGCGGCGGCGGCAGCGGCGGCGGCGGCAGC (SEQ ID NO: 154)

[0181] > STABILIZED FQQ-YTE-FC APEFQGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCQVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSGS FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 155)

[0182] > STABILIZED FQQ-YTE-FC nucleotide GCGCCGGAATTTCAGGGCGGCCCGAGCGTGTTTCTGTTTCCGCCGAAACCGAAAG ATACCCTGTATATTACCCGCGAACCGGAAGTGACCTGCGTGGTGGTGGATGTGAGC CATGAAGATCCGGAAGTGAAATTTAACTGGTATGTGGATGGCGTGGAAGTGCATAACGCGAAAACCAAACCGCGCGAAGAACAGTATAACAGCACCTATCGCGTGGTGA GCGTGCTGACCGTGCTGCATCAGGATTGGCTGAACGGCAAAGAATATAAATGCCA GGTGAGCAACAAAGCGCTGCCGGCGCCGATTGAAAAAACCATTAGCAAAGCGAA AGGCCAGCCGCGCGAACCGCAGGTGTATACCCTGCCGCCGAGCCGCGAAGAAAT GACCAAAAACCAGGTGAGCCTGACCTGCCTGGTGAAAGGCTTTTATCCGAGCGAT ATTGCGGTGGAATGGGAAAGCAACGGCCAGCCGGAAAACAACTATAAAACCACC CCGCCGGTGCTGGATAGCGGCAGCTTTTTTCTGTATAGCAAACTGACCGTGGATAA AAGCCGCTGGCAGCAGGGCAACGTGTTTAGCTGCAGCGTGATGCATGAAGCGCTG CATAACCATTATACCCAGAAAAGCCTGAGCCTGAGCCCGGGCAAA (SEQ ID NO: 156)

[0183] >Combined Transgene ATGAAAAGCATTTATTTTGTGGCGGGCCTGTTTGTGATGCTGGTGCAGGGCAGCTG GCAGCGCAGCCTGCAGGATACCGAAGAAAAAAGCCGCAGCTTTAGCGCGAGCCA GGCGGATCCGCTGAGCGATCCGGATCAGATGAACGAAGATAAACGCCATAGCCAG GGCACCTTTACCAGCGATTATAGCAAATATCTGGATAGCCGCCGCGCGCAGGATTT TGTGCAGTGGCTGATGAACACCAAACGCAACCGCAACAACATTGCGAAACGCCAT GATGAATTTGAACGCCATGCGGAAGGCACCTTTACCAGCGATGTGAGCAGCTATCT GGAAGGCCAGGCGGCGAAAGAATTTATTGCGTGGCTGGTGAAAGGCCGCGGCCG CCGCGATTTTCCGGAAGAAGTGGCGATTGTGGAAGAACTGGGCCGCCGCCATGCG GATGGCAGCTTTAGCGATGAAATGAACACCATTCTGGATAACCTGGCGGCGCGCG ATTTTATTAACTGGCTGATTCAGACCAAAATTACCGATCGCAAAGGCGGCGGCGGC AGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGCGCC GGAATTTCAGGGCGGCCCGAGCGTGTTTCTGTTTCCGCCGAAACCGAAAGATACC CTGTATATTACCCGCGAACCGGAAGTGACCTGCGTGGTGGTGGATGTGAGCCATG AAGATCCGGAAGTGAAATTTAACTGGTATGTGGATGGCGTGGAAGTGCATAACGC GAAAACCAAACCGCGCGAAGAACAGTATAACAGCACCTATCGCGTGGTGAGCGT GCTGACCGTGCTGCATCAGGATTGGCTGAACGGCAAAGAATATAAATGCCAGGTG AGCAACAAAGCGCTGCCGGCGCCGATTGAAAAAACCATTAGCAAAGCGAAAGGC CAGCCGCGCGAACCGCAGGTGTATACCCTGCCGCCGAGCCGCGAAGAAATGACC AAAAACCAGGTGAGCCTGACCTGCCTGGTGAAAGGCTTTTATCCGAGCGATATTG CGGTGGAATGGGAAAGCAACGGCCAGCCGGAAAACAACTATAAAACCACCCCGC CGGTGCTGGATAGCGGCAGCTTTTTTCTGTATAGCAAACTGACCGTGGATAAAAGCCGCTGGCAGCAGGGCAACGTGTTTAGCTGCAGCGTGATGCATGAAGCGCTGCATA ACCATTATACCCAGAAAAGCCTGAGCCTGAGCCCGGGCAAA (SEQ ID NO: 157)

[0184] To increase expression in adipocytes enabling a broad therapeutic index subcutaneously administered gene therapy for the treatment of type 2 diabetes and obesity, the SEQ ID No: 3 Enhancer / Regulator is added at an optimal distance upstream of the Kozak sequence using the hybrid intron spacer (which is itself separated from the Kozak sequence by a 23nt spacer. SEQ ID No: 3 is followed by a Core Chicken Beta- Actin Promoter and a CMV enhancer.

[0185] > Kozak sequence

[0186] GCCACCATGA (SEQ ID NO: 158)

[0187] >Pre Kozak spacer

[0188] GTTGGGTTGGACGCGTCGCTAGC (SEQ ID NO: 159)

[0189] >Seq 3 enhancer

[0190] GCGAAGCGCGCGGCGGGCGGGAG (SEQ ID NO: 3)

[0191] >CMV enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCATTGACGTCAATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGA GTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTAC GCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTGTGCCCAGTACA TGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTAC CATG (SEQ ID NO: 160)

[0192] The construct is delivered via a subcutaneous injection using a lipid nanoparticle formulation intended for adipocyte targeting and maximum localization to the subcutis. The produced and secreted therapeutic protein is intended to mediate systemic effect following optimal biodistribution from the subcutaneous area of injection.

[0193] Example 2

[0194] An FGF21 protein is vectorized with an Fc fragment for the treatment of NASH. The construct is intended for subcutaneous delivery with a DNA containing vector formulation.The vector is intended to deliver the DNA locally to the subcutaneous tissues, for local production and secretion but systemic biodistribution of the FGF21-Fc therapeutic protein.

[0195] >FGF21 MDSDETGFEHSGLWVSVLAGLLLGACQAHPIPDSSPLLQFGGQVRQRYLYTDDAQQ TEAHLEIREDGTVGGAADQSPESLLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSL HFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPHCDPAPRGPARFLPLPGLPG ALPEPPGILAPQPPDVGSSDPLAMVGPSQGRSPSYAS (SEQ ID NO: 161)

[0196] >FGF21 nucleotide ATGGATAGCGATGAAACCGGCTTTGAACATAGCGGCCTGTGGGTGAGCGTGCTGG CGGGCCTGCTGCTGGGCGCGTGCCAGGCGCATCCGATTCCGGATAGCAGCCCGCT GCTGCAGTTTGGCGGCCAGGTGCGCCAGCGCTATCTGTATACCGATGATGCGCAGC AGACCGAAGCGCATCTGGAAATTCGCGAAGATGGCACCGTGGGCGGCGCGGCGG ATCAGAGCCCGGAAAGCCTGCTGCAGCTGAAAGCGCTGAAACCGGGCGTGATTC AGATTCTGGGCGTGAAAACCAGCCGCTTTCTGTGCCAGCGCCCGGATGGCGCGCT GTATGGCAGCCTGCATTTTGATCCGGAAGCGTGCAGCTTTCGCGAACTGCTGCTGG AAGATGGCTATAACGTGTATCAGAGCGAAGCGCAT (SEQ ID NO: 162)

[0197] >FC APELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSGS FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 163)

[0198] >FC Nucleotide GCGCCGGAACTGCTGGGCGGCCCGAGCGTGTTTCTGTTTCCGCCGAAACCGAAA GATACCCTGTATATTACCCGCGAACCGGAAGTGACCTGCGTGGTGGTGGATGTGAG CCATGAAGATCCGGAAGTGAAATTTAACTGGTATGTGGATGGCGTGGAAGTGCATA ACGCGAAAACCAAACCGCGCGAAGAACAGTATAACAGCACCTATCGCGTGGTGA GCGTGCTGACCGTGCTGCATCAGGATTGGCTGAACGGCAAAGAATATAAATGCAA AGTGAGCAACAAAGCGCTGCCGGCGCCGATTGAAAAAACCATTAGCAAAGCGAA AGGCCAGCCGCGCGAACCGCAGGTGTATACCCTGCCGCCGAGCCGCGAAGAAAT GACCAAAAACCAGGTGAGCCTGACCTGCCTGGTGAAAGGCTTTTATCCGAGCGATATTGCGGTGGAATGGGAAAGCAACGGCCAGCCGGAAAACAACTATAAAACCACC CCGCCGGTGCTGGATAGCGGCAGCTTTTTTCTGTATAGCAAACTGACCGTGGATAA AAGCCGCTGGCAGCAGGGCAACGTGTTTAGCTGCAGCGTGATGCATGAAGCGCTG CATAACCATTATACCCAGAAAAGCCTGAGCCTGAGCCCGGGCAAA (SEQ ID NO: 164)

[0199] >3x GGGGS spacer

[0200] GGGGSGGGGSGGGGS (SEQ ID NO: 165)

[0201] >3x GGGGS spacer nucleotide GGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGC (SEQ ID NO: 166)

[0202] >Combined Therapeutic Transgene ATGGATAGCGATGAAACCGGCTTTGAACATAGCGGCCTGTGGGTGAGCGTGCTGG CGGGCCTGCTGCTGGGCGCGTGCCAGGCGCATCCGATTCCGGATAGCAGCCCGCT GCTGCAGTTTGGCGGCCAGGTGCGCCAGCGCTATCTGTATACCGATGATGCGCAGC AGACCGAAGCGCATCTGGAAATTCGCGAAGATGGCACCGTGGGCGGCGCGGCGG ATCAGAGCCCGGAAAGCCTGCTGCAGCTGAAAGCGCTGAAACCGGGCGTGATTC AGATTCTGGGCGTGAAAACCAGCCGCTTTCTGTGCCAGCGCCCGGATGGCGCGCT GTATGGCAGCCTGCATTTTGATCCGGAAGCGTGCAGCTTTCGCGAACTGCTGCTGG AAGATGGCTATAACGTGTATCAGAGCGAAGCGCATGGCGGCGGCGGCAGCGGCGG CGGCGGCAGCGGCGGCGGCGGCAGCGCGCCGGAACTGCTGGGCGGCCCGAGCGT GTTTCTGTTTCCGCCGAAACCGAAAGATACCCTGTATATTACCCGCGAACCGGAAG TGACCTGCGTGGTGGTGGATGTGAGCCATGAAGATCCGGAAGTGAAATTTAACTG GTATGTGGATGGCGTGGAAGTGCATAACGCGAAAACCAAACCGCGCGAAGAACA GTATAACAGCACCTATCGCGTGGTGAGCGTGCTGACCGTGCTGCATCAGGATTGGC TGAACGGCAAAGAATATAAATGCAAAGTGAGCAACAAAGCGCTGCCGGCGCCGA TTGAAAAAACCATTAGCAAAGCGAAAGGCCAGCCGCGCGAACCGCAGGTGTATA CCCTGCCGCCGAGCCGCGAAGAAATGACCAAAAACCAGGTGAGCCTGACCTGCC TGGTGAAAGGCTTTTATCCGAGCGATATTGCGGTGGAATGGGAAAGCAACGGCCA GCCGGAAAACAACTATAAAACCACCCCGCCGGTGCTGGATAGCGGCAGCTTTTTT CTGTATAGCAAACTGACCGTGGATAAAAGCCGCTGGCAGCAGGGCAACGTGTTTAGCTGCAGCGTGATGCATGAAGCGCTGCATAACCATTATACCCAGAAAAGCCTGAG CCTGAGCCCGGGCAAA (SEQ ID NO: 167)

[0203] To increase expression in the subcutis and thereby enable maximum potency per delivered genetic cassette, following a subcutaneous administration of the DNA with a localizing vector the SEQ ID No: 5 Enhancer / Regulator is added at an optimal distance upstream of the Kozak sequence. Leading Intron and pre-Kozak spacer serve as the proximal enhancers, the CMV distal enhancer is added to further augment activity of the CBA Core Promoter and the Kozak sequence is optimized for maximum processivity.

[0204] > Kozak

[0205] CGCCACCATGG (SEQ ID NO: 168)

[0206] >Pre-Kozak spacer

[0207] GTTGGGTTGGACGCGTCGCTAG (SEQ ID NO: 169)

[0208] >SEQ ID NO: 5 CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA

[0209] The DNA is delivered using a quinolipid nanoparticle formulation via a subcutaneous injection for the treatment of NASH.

[0210] Example 3

[0211] A parathyroid hormone gene is overexpressed in the subcutaneous tissues following delivery of the DNA encoding for said gene with a localizing vector targeting white subcutaneous adipocytes. The vector delivers the PTH gene as follows:

[0212] >PTH MIPAKDMAKVMIVMLAICFLTKSDGKSVKKRSVSEIQLMHNLGKHLNSMERVEWLR KKLQDVHNFVALGAPLAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNVLTKA KSQ (SEQ ID NO: 170)

[0213] >PTH nucleotideATGATTCCGGCGAAAGATATGGCGAAAGTGATGATTGTGATGCTGGCGATTTGCTT TCTGACCAAAAGCGATGGCAAAAGCGTGAAAAAACGCAGCGTGAGCGAAATTCA GCTGATGCATAACCTGGGCAAACATCTGAACAGCATGGAACGCGTGGAATGGCTG CGCAAAAAACTGCAGGATGTGCATAACTTTGTGGCGCTGGGCGCGCCGCTGGCGC CGCGCGATGCGGGCAGCCAGCGCCCGCGCAAAAAAGAAGATAACGTGCTGGTGG AAAGCCATGAAAAAAGCCTGGGCGAAGCGGATAAAGCGGATGTGAACGTGCTGA CCAAAGCGAAAAGCCAGTAA (SEQ ID NO: 171)

[0214] SEQ ID NO: 4 enhancer is inserted between the CMV Core Promoter and the CMV Distal Enhancer. The CMV Core Promoter is spaced 18 nucleotides upstream of the Kozak sequence using the following 18 nucleotide Pre-Kozak spacer.

[0215] > Pre-Kozak Spacer

[0216] GTTGGACGCGTCGCTAGC (SEQ ID NO: 148)

[0217] > Kozak Sequence

[0218] GCCACCATGA (SEQ ID NO: 158)

[0219] >SEQ ID NO: 4 CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC

[0220] Example 4

[0221] The present example utilizes the same construct as in Example 3, except without the Pre-Kozak Spacer, placing the CMV Core Promoter in immediate proximity to the Kozak Sequence. The zero-spacer approach positions SEQ ID NO: 4 within the previously determined range of 249 nucleotides upstream of the Kozak sequence with a O-nucleotide spacer.

[0222] Example 5

[0223] In the present example the therapeutic transgene from Example 2 is delivered via a non-viral vector by a subcutanous injection. The vector targets subcutaneous adipocytes for local expression of the therapeutic transgene.

[0224] >FGF21-FcATGGATAGCGATGAAACCGGCTTTGAACATAGCGGCCTGTGGGTGAGCGTGCTGG CGGGCCTGCTGCTGGGCGCGTGCCAGGCGCATCCGATTCCGGATAGCAGCCCGCT GCTGCAGTTTGGCGGCCAGGTGCGCCAGCGCTATCTGTATACCGATGATGCGCAGC AGACCGAAGCGCATCTGGAAATTCGCGAAGATGGCACCGTGGGCGGCGCGGCGG ATCAGAGCCCGGAAAGCCTGCTGCAGCTGAAAGCGCTGAAACCGGGCGTGATTC AGATTCTGGGCGTGAAAACCAGCCGCTTTCTGTGCCAGCGCCCGGATGGCGCGCT GTATGGCAGCCTGCATTTTGATCCGGAAGCGTGCAGCTTTCGCGAACTGCTGCTGG AAGATGGCTATAACGTGTATCAGAGCGAAGCGCATGGCGGCGGCGGCAGCGGCGG CGGCGGCAGCGGCGGCGGCGGCAGCGCGCCGGAACTGCTGGGCGGCCCGAGCGT GTTTCTGTTTCCGCCGAAACCGAAAGATACCCTGTATATTACCCGCGAACCGGAAG TGACCTGCGTGGTGGTGGATGTGAGCCATGAAGATCCGGAAGTGAAATTTAACTG GTATGTGGATGGCGTGGAAGTGCATAACGCGAAAACCAAACCGCGCGAAGAACA GTATAACAGCACCTATCGCGTGGTGAGCGTGCTGACCGTGCTGCATCAGGATTGGC TGAACGGCAAAGAATATAAATGCAAAGTGAGCAACAAAGCGCTGCCGGCGCCGA TTGAAAAAACCATTAGCAAAGCGAAAGGCCAGCCGCGCGAACCGCAGGTGTATA CCCTGCCGCCGAGCCGCGAAGAAATGACCAAAAACCAGGTGAGCCTGACCTGCC TGGTGAAAGGCTTTTATCCGAGCGATATTGCGGTGGAATGGGAAAGCAACGGCCA GCCGGAAAACAACTATAAAACCACCCCGCCGGTGCTGGATAGCGGCAGCTTTTTT CTGTATAGCAAACTGACCGTGGATAAAAGCCGCTGGCAGCAGGGCAACGTGTTTA GCTGCAGCGTGATGCATGAAGCGCTGCATAACCATTATACCCAGAAAAGCCTGAG CCTGAGCCCGGGCAAA (SEQ ID NO: 167)

[0225] Expression potency is enhanced by inserting SEQ ID NO: 7 upstream of the Kozak sequence in the preferred position. The construct uses an 18nt Pre-Kozak spacer and an EFlalpha promoter upstream of said spacer.

[0226] >EF-1 Alpha Promoter GTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTG CGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTC GGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGC CTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTG GTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTT TTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCC AAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAG AATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGTCTCGCG CCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTG CGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGA GGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGG GCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTC CAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGG AGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAG GCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATC TTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAG

[0227] (SEQ ID NO: 172)

[0228] >Pre-Kozak Spacer

[0229] GTTGGACGCGTCGCTAGC (SEQ ID NO: 148)

[0230] > Kozak Sequence

[0231] GCCACCATGG (SEQ ID NO: 147)

[0232] >SEQ ID NO: 7 CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG

[0233] SEQ ID NO: 7 is positioned in the functional location defined as 798 nucleotides upstream of the Pre-Kozak spacer, which is a 27nt spacer positioned immediately upstream of the Kozak sequence.

[0234] Example 6 - Effect of Enhancer- Spacer- Kozak Architecture on Expression

[0235] Nucleic acid constructs were generated comprising a coding sequence encoding a secreted reporter protein operably linked to a Kozak sequence. Constructs were designed either with or without an upstream enhancer sequence separated from the Kozak sequence by a spacer region.

[0236] Spacer sequences of varying lengths (0-52 nucleotides) were evaluated, including spacer lengths of 0-18 nucleotides and 18-23 nucleotides. Enhancer sequences comprisingGC-rich motifs and sequences corresponding to SEQ ID NO: 1-8 were positioned upstream of the spacer.

[0237] Constructs were delivered in vivo using a non-viral delivery system and expression of the encoded protein was quantified in serum. Constructs comprising the enhancer- spacer-Kozak architecture demonstrated increased expression relative to otherwise identical constructs lacking the enhancer sequence. In certain embodiments, expression was increased by at least 2-fold.

[0238] These results demonstrate that positioning of an enhancer sequence upstream of the Kozak sequence, separated by a defined spacer region, enhances expression of the encoded protein.

[0239] Example 7 - Spacer Length and Enhancer Position Optimization

[0240] A series of constructs were generated in which the position of the enhancer relative to the Kozak sequence was varied by modifying spacer length. Enhancer sequences were positioned at distances ranging from 0 to 52 nucleotides upstream of the Kozak sequence. Expression of the encoded protein was measured following in vivo delivery.

[0241] Constructs in which the enhancer was positioned within 0-52 nucleotides upstream of the Kozak sequence exhibited improved expression relative to constructs lacking the enhancer. In certain embodiments, positioning the enhancer within approximately 18-23 nucleotides upstream of the Kozak sequence resulted in increased and more consistent expression compared to other spacer lengths.

[0242] These results indicate that both the presence of the enhancer and its proximity to the Kozak sequence contribute to enhanced expression.

[0243] Example 8 - Multi-Enhancer Architectures

[0244] Constructs comprising multiple enhancer sequences were generated, including combinations of proximal and distal enhancer elements positioned upstream of the Kozak sequence.Expression levels were compared to constructs containing a single enhancer sequence. In certain embodiments, constructs comprising two or more enhancer sequences demonstrated increased expression relative to single-enhancer constructs, indicating that enhancer elements may function additively or synergistically.

[0245] These findings support the use of multiple enhancer sequences to further enhance expression.

[0246] Example 9 - Long-Range Positional Effects in Circular Constructs

[0247] Circular DNA constructs were generated comprising:

[0248] • a coding sequence,

[0249] • a polyadenylation signal downstream of the coding sequence, and

[0250] • an enhancer-spacer-Kozak architecture positioned at varying locations within the circular construct. The start position of the spacer sequence relative to the poly adenylation signal was varied across constructs.

[0251] Expression analysis revealed that constructs in which the spacer start position was located between approximately 2,000 and 7,500 nucleotides downstream of the polyadenylation signal exhibited robust and reproducible expression. In contrast, constructs in which the enhancer-spacer-Kozak architecture was positioned outside of this range exhibited reduced or inconsistent expression.

[0252] These results demonstrate that long-range positioning of the enhancer architecture within circular constructs can be an important determinant of expression.

[0253] Example 10 - Functional Boundary of Positional Window

[0254] To further evaluate positional dependence, constructs were generated in which the enhancer-spacer-Kozak architecture was positioned both within and outside of the defined positional window.

[0255] When positioned within approximately 2,031 to 7,271 nucleotides downstream of the polyadenylation signal, constructs exhibited robust expression of the encoded protein. When positioned outside of this range, expression was:• significantly reduced,

[0256] • inconsistent across replicates, and / or

[0257] • below the lower limit of quantification (LLoQ). In certain embodiments, expression outside the defined positional window was not reliably detectable.

[0258] These results demonstrate a non-linear dependence of gene expression on positional architecture, in embodiments, and establish a functional boundary for enhancer activity within circular constructs.

[0259] Example 11 - Overcoming Size-Dependent Expression Loss

[0260] Constructs of varying sizes were generated to evaluate the relationship between construct length and expression.

[0261] Constructs lacking enhancer sequences exhibited reduced expression as construct size increased. In contrast, constructs comprising the enhancer-spacer-Kozak architecture maintained or increased expression despite increases in construct size. In certain embodiments, expression levels exceeded those predicted based on the inverse relationship between construct size and expression.

[0262] These findings demonstrate that the enhancer architecture described herein can overcome size-dependent limitations in gene expression.

[0263] Example 12 - Applicability Across Therapeutic Payloads

[0264] Constructs encoding different classes of proteins were generated, including:

[0265] • secreted reporter proteins,

[0266] • peptide hormones, and

[0267] • fusion proteins. Enhancer-spacer-Kozak architectures were incorporated into each construct.

[0268] Across multiple payload classes, constructs comprising the enhancer architecture demonstrated increased expression relative to constructs lacking the enhancer.These results indicate that the invention is broadly applicable across different coding sequences and protein classes.

[0269] Example 13 - Subcutaneous Delivery and Systemic Expression

[0270] Constructs comprising the enhancer-spacer-Kozak architecture were administered subcutaneously using a non-viral delivery system. Expression of the encoded protein was detected in circulation, indicating systemic distribution following local delivery.

[0271] Constructs comprising the enhancer architecture exhibit higher circulating protein levels relative to control constructs lacking the enhancer.

[0272] These results demonstrate that the described constructs are suitable for subcutaneous gene delivery applications.

[0273] EMBODIMENTS OF THE INVENTION

[0274] 1. Therapeutic gene therapy formulations for the treatment of human or veterinary pathologies comprised of:

[0275] a. an adipocyte-targeting, subcutaneously administered, or subcutaneously localizing nucleic acid delivery vector,

[0276] b. intended for predominantly subcutaneous administration of DNA, c. for production of secreted therapeutic proteins or peptides,

[0277] d. with the goal of mediating distal or systemic therapeutic effect, e. which contain at least one upstream enhancer positioned with at least one spacer upstream of the Kozak sequence and delivered in cis with the therapeutic transgene.

[0278] 2. Pre-Kozak spacers, which are 0 to 18 nt in length.

[0279] 3. Pre-Kozak spacers, which are 0 to 23 nt in length.

[0280] 4. Pre-Kozak spacers, which are 0 to 52 nt in length.

[0281] 5. Enhancer in Claim 1, which is an upstream enhancer C[A / G]GGTT[G / T]G, positioned with a 0-18nt spacer upstream of the Kozak sequence.

[0282] 6. Enhancer in Claim 1, which is an upstream enhancer C[A / G]GGTT[G / T]G, positioned with a 0-23nt spacer upstream of the Kozak sequence.Enhancer in Claim 1, which is an upstream enhancer C[A / G]GGTT[G / T]G, positioned with a 0-52nt spacer upstream of the Kozak sequence.

[0283] Enhancer in Claim 1, which is an upstream enhancer from a class of Series A sequences, positioned with a 0-18nt spacer upstream of the Kozak sequence.

[0284] Enhancer in Claim 1, which is an upstream enhancer from a class of Series A sequences, positioned with a 0-23nt spacer upstream of the Kozak sequence.

[0285] Enhancer in Claim 1, which is an upstream enhancer GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCA GGGCTCAGGATA (SEQ ID NO: 8), positioned with a 0-18nt spacer upstream of the Kozak sequence.

[0286] Enhancer in Claim 1, which is an upstream enhancer GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCA GGGCTCAGGATA (SEQ ID NO: 8), positioned with a 0-23nt spacer upstream of the Kozak sequence.

[0287] Enhancer in Claim 1, which is an upstream enhancer GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCA GGGCTCAGGATA (SEQ ID NO: 8), positioned with a 0-52nt spacer upstream of the Kozak sequence.

[0288] Enhancer in Claim 1, which is an upstream enhancer from a class of Series A sequences, positioned with a 0-52nt spacer upstream of the Kozak sequence.

[0289] Enhancer in Claim 1, which is an upstream enhancer ACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG (SEQ ID NO: 2), positioned with a 0-18nt spacer upstream of the Kozak sequence.

[0290] Enhancer in Claim 1, which is an upstream enhancer ACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG (SEQ ID NO: 2), positioned with a 0-23nt spacer upstream of the Kozak sequence.

[0291] Enhancer in Claim 1, which is an upstream enhancer ACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG (SEQ ID NO: 2), positioned with a 0-52nt spacer upstream of the Kozak sequence.

[0292] Enhancer in Claim 1, which is an upstream enhancer CAGGTTGG, positioned with a 0-18nt spacer upstream of the Kozak sequence.

[0293] Enhancer in Claim 1, which is an upstream enhancer CAGGTTGG, positioned with a 0-23nt spacer upstream of the Kozak sequence.Enhancer in Claim 1, which is an upstream enhancer CAGGTTGG, positioned with a 0-52nt spacer upstream of the Kozak sequence.

[0294] Enhancer in Claim 1, which is an upstream enhancer from a class of Series G sequences, positioned with a 0-18nt spacer upstream of the Kozak sequence.

[0295] Enhancer in Claim 1, which is an upstream enhancer from a class of Series G sequences, positioned with a 0-23nt spacer upstream of the Kozak sequence.

[0296] Enhancer in Claim 1, which is an upstream enhancer from a class of Series G sequences, positioned with a 0-52nt spacer upstream of the Kozak sequence.

[0297] Enhancer in Claim 1, which is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG (SEQ ID NO: 3), positioned 316 to 264nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0298] Enhancer in Claim 1, which is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG (SEQ ID NO: 3), positioned 316 to 264nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0299] Enhancer in Claim 1, which is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG (SEQ ID NO: 3), positioned 316 to 264nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0300] Enhancer in Claim 1, which is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG (SEQ ID NO: 3), positioned 251 to 199nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0301] Enhancer in Claim 1, which is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG (SEQ ID NO: 3), positioned 251 to 199nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0302] Enhancer in Claim 1, which is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG (SEQ ID NO: 3), positioned 251 to 199nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.Enhancer in Claim 1, which is an upstream enhancer from a Class of Series B sequences, positioned 316 to 264nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0303] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series B sequences, positioned 316 to 264nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0304] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series B sequences, positioned 316 to 264nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0305] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series B sequences, positioned 251 to 199nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0306] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series B sequences, positioned 251 to 199nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0307] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series B sequences, positioned 251 to 199nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0308] Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), positioned 615 to 563nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0309] Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), positioned 615 to 563nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0310] Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), positioned 615 to 563nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0311] Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), positioned 581 to 529nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), positioned 581 to 529nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0312] Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), positioned 581 to 529nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0313] Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), positioned 932 to 840nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0314] Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), positioned 932 to 840nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0315] Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), positioned 932 to 840nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0316] Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), positioned 295 to 203nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0317] Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), positioned 295 to 203nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0318] Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ ID NO: 4), positioned 295 to 203nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0319] Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC (SEQ IDNO: 4), positioned 581 to 529nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0320] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 615 to 563nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0321] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 615 to 563nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0322] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 615 to 563nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0323] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 581 to 529nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0324] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 581 to 529nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0325] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 581 to 529nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0326] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 932 to 840nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0327] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 932 to 840nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0328] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 932 to 840nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0329] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 295 to 203nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 295 to 203nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0330] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 295 to 203nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0331] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 850 to 798nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0332] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 850 to 798nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0333] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 850 to 798nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0334] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 798 to 746nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0335] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 798 to 746nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0336] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 798 to 746nt upstream of the Kozaksequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0337] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0338] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0339] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0340] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 746 to 682nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0341] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 746 to 682nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0342] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 746 to 682nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0343] Enhancer in Claim 1, which is an upstream enhancer

[0344] CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCA (SEQ ID NO: 5), positioned 529 to 413nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0345] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 529 to 413nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0346] Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA (SEQ ID NO: 5), positioned 529 to 413nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0347] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 850 to 798nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0348] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 850 to 798nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0349] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 850 to 798nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0350] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 798 to 746nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0351] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 798 to 746nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0352] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 798 to 746nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0353] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 746 to 682nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 746 to 682nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0354] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 746 to 682nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0355] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 529 to 413nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0356] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 529 to 413nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0357] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 529 to 413nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0358] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0359] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0360] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0361] Enhancer in Claim 1, which is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC (SEQ ID NO: 6), positioned 232 to 180nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0362] Enhancer in Claim 1, which is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC (SEQ ID NO: 6), positioned 232 to 180nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0363] Enhancer in Claim 1, which is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC (SEQ ID NO: 6),positioned 232 to 180nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0364] Enhancer in Claim 1, which is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC (SEQ ID NO: 6), positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0365] Enhancer in Claim 1, which is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC (SEQ ID NO: 6), positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0366] Enhancer in Claim 1, which is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC (SEQ ID NO: 6), positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0367] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series E sequences, positioned 232 to 180nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0368] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series E sequences, positioned 232 to 180nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0369] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series E sequences, positioned 232 to 180nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0370] Enhancer in Claim 1, which is an upstream enhancer from a Class of Series E sequences, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0371] . Enhancer in Claim 1, which is an upstream enhancer from a Class of Series E sequences, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0372] . Enhancer in Claim 1, which is an upstream enhancer from a Class of Series E sequences, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0373] . Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG (SEQ IDNO: 7), positioned 84 to 32nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0374] . Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG (SEQ ID NO: 7), positioned 84 to 32nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0375] . Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG (SEQ ID NO: 7), positioned 84 to 32nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0376] . Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG (SEQ ID NO: 7), positioned 1031 to 979nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0377] . Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG (SEQ ID NO: 7), positioned 1031 to 979nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0378] . Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG (SEQ ID NO: 7), positioned 1031 to 979nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0379] . Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG (SEQ ID NO: 7), positioned 843 to 753nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0380] . Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG (SEQ ID NO: 7), positioned 843 to 753nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0381] . Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG (SEQ ID NO: 7), positioned 843 to 753nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 84 to 32nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0382] . Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 84 to 32nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0383] . Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 84 to 32nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0384] . Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0385] . Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0386] . Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0387] . Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 843 to 753nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

[0388] . Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 843 to 753nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

[0389] . Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 843 to 753nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

[0390] . An enhancer in Claim 1, which is any of the sequences listed in the application positioned upstream of the Kozak sequence with a 0-18 nucleotide spacer.

[0391] . An enhancer in Claim 1, which is any of the sequences listed in the application positioned upstream of the Kozak sequence with a 0-23 nucleotide spacer.

[0392] . An enhancer in Claim 1, which is any of the sequences listed in the application positioned upstream of the Kozak sequence with a 0-52 nucleotide spacer.. Spacer in Claim 1, which is GTTGGACGCGTCGCTAGC (SEQ ID NO: 148) or a sequence of >85% identity.

[0393] . Spacer in Claim 1, which is GTCCACTCCCAGTTCAATTCACTGTGCACCGGTCGTTGGACGCGTCGCTAG

[0394] C (SEQ ID NO: 149) or a sequence of >85% identity.

[0395] . Spacer in Claim 1, which is AAGCTGTTGGACGCGTCGCTAGC (SEQ ID NO: 150) or a sequence of >85% identity.

[0396] . Therapeutic proteins or peptides in Claim 1, which are derived from a class of incretins.

[0397] . Therapeutic proteins or peptides in Claim 1, which are derived from a class of antibodies.

[0398] . Therapeutic proteins or peptides in Claim 1, which are derived from a class of human secreted proteins.

[0399] . Therapeutic proteins or peptides in Claim 1, which are derived from a class of antibody fragments.

[0400] . Therapeutic proteins or peptides in Claim 1, which are derived from a class of fusion proteins.

[0401] . Therapeutic protein in Claim 1, which is a fibroblast growth factor family protein.

[0402] . Therapeutic protein in Claim 1, which is a transforming growth factor-beta (TGF-P) family protein.

[0403] . Therapeutic protein in Claim 1, which is a tumor necrosis factor (TNF) family protein.

[0404] . Therapeutic protein in Claim 1, which is an interleukin family protein.

[0405] . Therapeutic protein in Claim 1, which is an interleukin receptor antagonist family protein.

[0406] . Therapeutic protein in Claim 1, which is an interferon family protein.

[0407] . Therapeutic protein in Claim 1, which is an interferon receptor antagonist family protein.

[0408] . Therapeutic protein in Claim 1, which is a colony- stimulating factor (CSF) family protein.

[0409] . Therapeutic protein in Claim 1, which is a chemokine family protein.

[0410] . Therapeutic protein in Claim 1, which is a vascular endothelial growth factor (VEGF) family protein.. Therapeutic protein in Claim 1, which is an epidermal growth factor (EGF) family protein.

[0411] . Therapeutic protein in Claim 1, which is a hepatocyte growth factor (HGF) family protein.

[0412] . Therapeutic protein in Claim 1, which is a platelet-derived growth factor (PDGF) family protein.

[0413] . Therapeutic protein in Claim 1, which is an insulin-like growth factor (IGF) family protein.

[0414] . Therapeutic protein in Claim 1, which is a bone morphogenetic protein (BMP) family protein.

[0415] . Therapeutic protein in Claim 1, which is a glial cell line-derived neurotrophic factor (GDNF) family protein,

[0416] . Therapeutic protein in Claim 1, which is a neuro trophin family protein.

[0417] . Therapeutic protein in Claim 1, which is a growth differentiation factor (GDF) family protein.

[0418] . Therapeutic protein in Claim 1, which is a Wnt family protein.

[0419] . Therapeutic protein in Claim 1, which is a hedgehog family protein.

[0420] . Therapeutic protein in Claim 1, which is a transforming growth factor- alpha (TGF-a) family protein.

[0421] . Therapeutic protein in Claim 1, which is a resistin-like molecule (RELM) family protein.

[0422] . Therapeutic protein in Claim 1, which is an angiopoietin family protein.

[0423] . Therapeutic protein in Claim 1, which is a galectin family protein.

[0424] . Therapeutic protein in Claim 1, which is a secreted frizzled-related protein (sFRP) family protein.

[0425] . Therapeutic protein in Claim 1, which is a cystatin family protein.

[0426] . Therapeutic protein in Claim 1, which is a serpin family protein.

[0427] . Therapeutic protein in Claim 1, which is a cytokine.

[0428] . Therapeutic protein in Claim 1, which is a cytokine receptor antagonist.

[0429] . Therapeutic protein in Claim 1, which is a defensin family protein.

[0430] . Therapeutic protein in Claim 1, which is a cathelicidin family protein.

[0431] . Therapeutic protein in Claim 1, which is a lectin family protein.

[0432] . Therapeutic protein in Claim 1, which is a prolactin / growth hormone family protein.. Therapeutic peptide in Claim 1, which is a gastric inhibitor peptide or derivative.

[0433] . Therapeutic peptide in Claim 1, which is a GLP-1 or derivative.

[0434] . Therapeutic peptide in Claim 1, which is a glucagon or derivative.

[0435] . Therapeutic peptide in Claim 1, which is an amylin or derivative.

[0436] . Therapeutic protein in Claim 1, which is a protein fused to an albumin peptide.

[0437] . Therapeutic protein in Claim 1, which is a protein fused to an Fc-binding peptide.

[0438] . Therapeutic protein in Claim 1, which is a protein fused to an Fc-fragment. . Therapeutic protein in Claim 1, which is a protein fused to a globulin binding peptide.

[0439] . DNA in Claim 1, which is circular double stranded DNA.

[0440] . DNA in Claim 1, which is linear double stranded DNA.

[0441] . DNA in Claim 1, which is circular single stranded DNA.

[0442] . DNA in Claim 1, which is linear single stranded DNA.

[0443] . DNA in Claim 1, which is covalently closed DNA.

[0444] . DNA in Claim 1, which is chemically modified DNA.

[0445] . DNA in Claim 1, which is a DNA / RNA hybrid.

[0446] . DNA in Claim 1, which is chemically conjugated to peptides or small molecules.

[0447] . Vectors in Claim 1, which are non- viral vectors.

[0448] . Vectors in Claim 1, which are lipid nanoparticles.

[0449] . Vectors in Claim 1, which are liposomes.

[0450] . Vectors in Claim 1, which are lipid micelles.

[0451] . Vectors in Claim 1, which are carbon nanotubes.

[0452] . Vectors in Claim 1, which are nano emulsion droplets.

[0453] . Vectors in Claim 1, which are lipid bilayer sheets.

[0454] . Vectors in Claim 1, which are polyelectrolytic complexes.

[0455] . Vectors in Claim 1, which are polymeric nanoparticles.

[0456] . Vectors in Claim 1, which are dendrimers.

[0457] . Vectors in Claim 1, which are polymers.

[0458] . Vectors in Claim 1, which are biopolymers.

[0459] . Vectors in Claim 1, which are bioresorbable polymers.. Vectors in Claim 1, which are polyethyleneimine complexes.

[0460] . Vectors in Claim 1, which are solid lipid nanoparticles.

[0461] . Vectors in Claim 1, which are exosomes.

[0462] . Vectors in Claim 1, which are micelles.

[0463] . Vectors in Claim 1, which are cell-penetrating peptides.

[0464] . Vectors in Claim 1, which are cationic emulsions.

[0465] . Vectors in Claim 1, which are calcium phosphate nanoparticles.

[0466] . Vectors in Claim 1, which are silica nanoparticles.

[0467] . Vectors in Claim 1, which are metallic nanoparticles.

[0468] . Vectors in Claim 1, which are ceramic nanoparticles.

[0469] . Vectors in Claim 1, which are DNA nanostructures.

[0470] . Vectors in Claim 1, which are naked plasmid DNA formulations.

[0471] . Vectors in Claim 1, which are non-viral vectors functionalized with peptides, polymers, monosaccharides, polysaccharides, oligosaccharides, antibodies, fragments, or proteins.

[0472] . Vectors in Claim 1, which are combinations of one or more non-viral vector gene therapies.

[0473] . Vector in Claim 1, which is a viral vector or combination of viral vectors. . Vector in Claim 1, wherein the vector is adenovirus.

[0474] . Vector in Claim 1, wherein the vector is lentivirus.

[0475] . Vector in Claim 1, wherein the vector is retrovirus.

[0476] . Vector in Claim 1, wherein the vector is herpes simplex virus.

[0477] . Vector in Claim 1, wherein the vector is vaccinia virus or Modified Vaccinia Ankara (MVA).

[0478] . Vector in Claim 1, wherein the vector is cytomegalovirus.

[0479] . Vector in Claim 1, wherein the vector is comprised of one or more of an Alphacoronavirus, Alphaherpesvirus, Alpharetrovirus, Alphavirus, Anellovirus, Astrovirus, Avulavirus, Betacoronavirus, Betaherpesvirus, Betaretrovirus, Bornavirus, Bunyavirus, Calicivirus, Circovirus, Coxsackievirus, Deltacoronavirus, Deltaretrovirus, Dengue virus, Ebolavirus, Enterovirus, Filovirus, Flavivirus, Gammacoronavirus, Gammaherpesvirus, Hantavirus, Hepacivirus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, Human immunodeficiency virus (HIV), Human papillomavirus (HPV), Influenza virus, Lyssavirus, Marburgvirus, Measles virus, Metapneumovirus, Mumps virus,Norovirus, Orthohantavirus, Orthomyxovirus, Parainfluenza virus, Parechovirus, Picomavirus, Poliovirus, Polyomavirus, Rabies virus, Reovirus, Respiratory syncytial virus (RSV), Rhinovirus, Rotavirus, Rubivirus, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Simian foamy virus, Tenuivirus, Togavirus, Varicellazoster virus, Variola virus (Smallpox virus), Vesiculovirus, West Nile virus, Yellow fever virus, Zika virus, and a nucleic acid sequence encoding a therapeutic transgene, wherein the composition is configured for subcutaneous administration.

[0480] . Administration in Claim 1, which is a subcutaneous injection.

[0481] . Administration in Claim 1, which is at least in part an intravenous injection of a formulation that targets adipocytes.

[0482] . Administration in Claim 1, which is an intravenous injection of a formulation that targets subcutaneous adipocytes.

[0483] . Administration in Claim 1, which is a subcutaneous infusion.

[0484] . Administration in Claim 1, which is performed via an autoinjector, patch injector, pen injector, syringe, patch, jet injector, or via microneedles.

[0485] . Pathologies in Claim 1, which are one or more of Hypertension, coronary artery disease, heart failure, stroke, atrial fibrillation, peripheral artery disease, type 2 diabetes mellitus, type 1 diabetes, obesity, hyperlipidemia, metabolic syndrome, hypothyroidism, polycystic ovary syndrome, chronic obstructive pulmonary disease, asthma, pneumonia, pulmonary fibrosis, lung cancer, Alzheimer’s disease, Parkinson’s disease, epilepsy, migraine, multiple sclerosis, depression, anxiety disorders, bipolar disorder, schizophrenia, substance use disorders, gastroesophageal reflux disease, irritable bowel syndrome, inflammatory bowel disease, hepatitis B, hepatitis C, liver cirrhosis, breast cancer, prostate cancer, colorectal cancer, pancreatic cancer, leukemias, lymphomas, osteoarthritis, rheumatoid arthritis, osteoporosis, low back pain, HIV / AIDS, tuberculosis, malaria, influenza, COVID-19, human papillomavirus infection, hepatitis A, hepatitis D, hepatitis E, acne vulgaris, psoriasis, atopic dermatitis, basal cell carcinoma, squamous cell carcinoma, melanoma, chronic kidney disease, urinary tract infections, nephrolithiasis, benign prostatic hyperplasia, infertility, endometriosis, uterine fibroids, erectile dysfunction or related diseases. . Pathologies in Claim 1, which are derived from a class of autoimmune disorders, monogenic conditions, reproductive disorders, renal & urological diseases, dermatologic conditions, infectious diseases, musculoskeletal disorders, oncologies, gastrointestinal disorders, psychiatric & behavioral conditions, neurological disorders,respiratory diseases, metabolic & endocrine disorders, cardiovascular diseases or related pathologies.

Claims

CLAIMSWhat is claimed is:

1. A circular nucleic acid construct comprising:• a coding sequence encoding a protein or peptide;• a polyadenylation signal positioned downstream of the coding sequence;• a Kozak sequence operably linked to the coding sequence;• a spacer sequence positioned upstream of the Kozak sequence; and• at least one enhancer sequence positioned upstream of the Kozak sequence and separated from the Kozak sequence by the spacer sequence,wherein:• the enhancer sequence is positioned within 0 to 52 nucleotides upstream of the Kozak sequence;• the spacer sequence is between 0 and 52 nucleotides in length; and• a start position of the spacer sequence is located between 2,031 and 7,271 nucleotides downstream of the polyadenylation signal,wherein positioning of the enhancer-spacer-Kozak architecture within said range results in increased expression of the encoded protein relative to positioning outside said range.

2. The construct of claim 1, wherein the enhancer sequence comprises a sequence having at least 85% identity to a sequence selected from:• C[A / G]GGTT[G / T]G• GCGAAGCGCGCGGCGGGCGGGAG• CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC• CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC CCGCCCA• GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC• CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG• GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCA GGGCTCAGGATAand is positioned within 0 to 52 nucleotides upstream of the Kozak sequence.

3. The construct of claim 2, wherein the enhancer sequence is positioned between 18 and 23 nucleotides upstream of the Kozak sequence.

4. The construct of claim 2, wherein the spacer sequence is between 0 and 18 nucleotides in length.

5. The construct of claim 2, wherein:• the enhancer sequence is positioned between 18 and 23 nucleotides upstream of the Kozak sequence; and• the spacer sequence is between 0 and 18 nucleotides in length.

6. The construct of claim 1, wherein the enhancer sequence comprises:• a GC-rich sequence,• a CpG-rich sequence, or• a motif of the form C[A / G]GGTT[G / T]G.

7. The construct of claim 6, wherein the enhancer sequence is positioned between 18 and 23 nucleotides upstream of the Kozak sequence.

8. The construct of claim 1, wherein the spacer sequence comprises:GTTGGACGCGTCGCTAGC or a sequence having at least 85% identity thereto.

9. The construct of claim 1, wherein the spacer sequence lacks translation initiation codons.

10. The construct of claim 1, comprising a plurality of enhancer sequences.

11. The construct of claim 10, wherein the plurality of enhancer sequences comprises:• a proximal enhancer positioned within 0-52 nucleotides upstream of the Kozak sequence; and• a distal enhancer positioned upstream of the proximal enhancer.

12. A circular nucleic acid construct comprising:• a coding sequence;• a polyadenylation signal downstream of the coding sequence; and• an enhancer-spacer- Kozak architecture according to claim 1,wherein the start position of the spacer sequence is located between 2,000 and 7,500 nucleotides downstream of the polyadenylation signal.

13. The construct of claim 12, wherein the start position is between 2,031 and 7,271 nucleotides downstream of the polyadenylation signal.

14. The construct of claim 12, wherein positioning of the enhancer-spacer-Kozak architecture outside the defined range results in reduced or non-detectable expression.

15. The construct of claim 1, wherein expression is increased by at least 2-fold relative to a construct lacking the enhancer sequence.

16. The construct of claim 1, wherein inclusion of the enhancer sequence increases expression beyond levels predicted based on construct size.

17. The construct of claim 1, wherein the encoded protein is selected from:• GLP- 1 or a variant thereof• FGF21• an antibody or antibody fragment• a cytokine or growth factorand is optionally fused to an Fc-receptor binding domain, albumin binding domain, or other fusion partner.

18. Enhancer in Claim 1, which is an upstream enhancer C[A / G]GGTT[G / T]G, positioned with a 0-18nt spacer upstream of the Kozak sequence.

19. Enhancer in Claim 1, which is an upstream enhancer C[A / G]GGTT[G / T]G, positioned with a 0-23nt spacer upstream of the Kozak sequence.

20. Enhancer in Claim 1, which is an upstream enhancer C[A / G]GGTT[G / T]G, positioned with a 0-52nt spacer upstream of the Kozak sequence.

21. Enhancer in Claim 1, which is an upstream enhancer from a class of Series A sequences, positioned with a 0-18nt spacer upstream of the Kozak sequence.

22. Enhancer in Claim 1, which is an upstream enhancer from a class of Series A sequences, positioned with a 0-23nt spacer upstream of the Kozak sequence.

23. Enhancer in Claim 1, which is an upstream enhancer GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCAGGGCT CAGGATA, positioned with a 0-18nt spacer upstream of the Kozak sequence.

24. Enhancer in Claim 1, which is an upstream enhancer GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCAGGGCT CAGGATA, positioned with a 0-23nt spacer upstream of the Kozak sequence.

25. Enhancer in Claim 1, which is an upstream enhancer GGATGTGCCATGTGAGTCTGCCTTTCCCATGACTATTCACCTGTCAATTTCAGGGCT CAGGATA, positioned with a 0-52nt spacer upstream of the Kozak sequence.

26. Enhancer in Claim 1, which is an upstream enhancer from a class of Series A sequences, positioned with a 0-52nt spacer upstream of the Kozak sequence.

27. Enhancer in Claim 1, which is an upstream enhancer ACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG, positioned with a 0-18nt spacer upstream of the Kozak sequence.

28. Enhancer in Claim 1, which is an upstream enhancer ACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG, positioned with a 0-23nt spacer upstream of the Kozak sequence.

29. Enhancer in Claim 1, which is an upstream enhancer ACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGG, positioned with a 0-52nt spacer upstream of the Kozak sequence.

30. Enhancer in Claim 1, which is an upstream enhancer CAGGTTGG, positioned with a 0-18nt spacer upstream of the Kozak sequence.

31. Enhancer in Claim 1, which is an upstream enhancer CAGGTTGG, positioned with a 0-23nt spacer upstream of the Kozak sequence.

32. Enhancer in Claim 1, which is an upstream enhancer CAGGTTGG, positioned with a 0-52nt spacer upstream of the Kozak sequence.

33. Enhancer in Claim 1, which is an upstream enhancer from a class of Series G sequences, positioned with a 0-18nt spacer upstream of the Kozak sequence.

34. Enhancer in Claim 1, which is an upstream enhancer from a class of Series G sequences, positioned with a 0-23nt spacer upstream of the Kozak sequence.

35. Enhancer in Claim 1, which is an upstream enhancer from a class of Series G sequences, positioned with a 0-52nt spacer upstream of the Kozak sequence.

36. Enhancer in Claim 1, which is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG, positioned 316 to 264nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

37. Enhancer in Claim 1, which is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG, positioned 316 to 264nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

38. Enhancer in Claim 1, which is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG, positioned 316 to 264nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

39. Enhancer in Claim 1, which is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG, positioned 251 to 199nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

40. Enhancer in Claim 1, which is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG, positioned 251 to 199nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

41. Enhancer in Claim 1, which is an upstream enhancer GCGAAGCGCGCGGCGGGCGGGAG, positioned 251 to 199nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

42. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series B sequences, positioned 316 to 264nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

43. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series B sequences, positioned 316 to 264nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

44. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series B sequences, positioned 316 to 264nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

45. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series B sequences, positioned 251 to 199nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

46. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series B sequences, positioned 251 to 199nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

47. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series B sequences, positioned 251 to 199nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

48. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 615 to 563nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

49. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 615 to 563nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

50. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 615 to 563nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

51. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 581 to 529nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

52. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 581 to 529nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

53. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 581 to 529nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

54. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 932 to 840nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

55. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 932 to 840nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

56. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 932 to 840nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

57. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 295 to 203nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

58. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 295 to 203nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

59. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 295 to 203nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

60. Enhancer in Claim 1, which is an upstream enhancer CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC, positioned 581to 529nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

61. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 615 to 563nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

62. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 615 to 563nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

63. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 615 to 563nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

64. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 581 to 529nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

65. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 581 to 529nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

66. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 581 to 529nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

67. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 932 to 840nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

68. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 932 to 840nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

69. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 932 to 840nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

70. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 295 to 203nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

71. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 295 to 203nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

72. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series C sequences, positioned 295 to 203nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

73. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 850 to 798nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

74. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 850 to 798nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

75. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 850 to 798nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

76. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 798 to 746nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

77. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 798 to 746nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

78. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 798 to 746nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

79. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

80. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

81. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

82. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 746 to 682nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

83. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 746 to 682nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

84. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 746 to 682nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

85. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 529 to 413nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

86. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 529 to 413nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

87. Enhancer in Claim 1, which is an upstream enhancer CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC CCA, positioned 529 to 413nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

88. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 850 to 798nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

89. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 850 to 798nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

90. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 850 to 798nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

91. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 798 to 746nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

92. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 798 to 746nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

93. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 798 to 746nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

94. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 746 to 682nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

95. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 746 to 682nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

96. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 746 to 682nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

97. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 529 to 413nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

98. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 529 to 413nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

99. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 529 to 413nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

100. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

101. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

102. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series D sequences, positioned 1166 to 1050nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

103. Enhancer in Claim 1, which is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, positioned 232 to 180nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

104. Enhancer in Claim 1, which is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, positioned 232 to 180nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

105. Enhancer in Claim 1, which is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, positioned 232 to 180nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

106. Enhancer in Claim 1, which is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

107. Enhancer in Claim 1, which is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

108. Enhancer in Claim 1, which is an upstream enhancer GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC, positioned 1179 to 1127ntupstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

109. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series E sequences, positioned 232 to 180nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

110. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series E sequences, positioned 232 to 180nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

111. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series E sequences, positioned 232 to 180nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

112. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series E sequences, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

113. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series E sequences, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

114. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series E sequences, positioned 1179 to 1127nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

115. Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 84 to 32nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

116. Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 84 to 32nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

117. Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 84 to 32nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

118. Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 1031to 979nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

119. Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

120. Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

121. Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 843 to 753nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

122. Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 843 to 753nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

123. Enhancer in Claim 1, which is an upstream enhancer CCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG, positioned 843 to 753nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

124. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 84 to 32nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

125. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 84 to 32nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

126. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 84 to 32nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

127. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

128. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

129. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 1031 to 979nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.

130. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 843 to 753nt upstream of the Kozak sequence with a 0-18nt spacer between the end of the enhancer and the Kozak sequence.

131. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 843 to 753nt upstream of the Kozak sequence with a 0-23nt spacer between the end of the enhancer and the Kozak sequence.

132. Enhancer in Claim 1, which is an upstream enhancer from a Class of Series F sequences, positioned 843 to 753nt upstream of the Kozak sequence with a 0-52nt spacer between the end of the enhancer and the Kozak sequence.